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Amyotrophic lateral sclerosis (ALS) is the most common fatal neurodegenerative disease, 
resulting in loss of voluntary muscle control, atrophy, paralysis, and eventually death.  
Although the pathophysiology of ALS is not completely understood, recent research in 
Dr. Chin’s lab has identified alterations in skeletal muscle proteins in ALS mice.  The 
purpose of this study was to investigate alterations in proteins involved in calcium 
handling (SERCA1 and SERCA2), endoplasmic reticulum (ER) stress (Grp78/BiP, PDI, 
and CHOP) and protein synthesis (Akt) in human ALS skeletal muscle.  The ER 
chaperone protein Grp78/BiP and Akt, a protein involved in protein synthesis, were 
higher in ALS compared to CON.  The calcium pump SERCA1 was lower in diaphragm 
compared to quadriceps muscles of ALS cases.  These data highlight alterations in 
skeletal muscle proteins not only between ALS and CON, but also between different 
muscles in ALS, which are helpful for informing future research study designs.  
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Chapter 1: Introduction 
Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, is the 
most common fatal neurodegenerative disorder in adults, with approximately 4 cases of 
ALS per 100,000 persons in the United States (103).  ALS involves loss of neurons in 
both the brain and spinal cord (upper and lower motor neurons) that control voluntary 
muscle movement.  The disease is characterized by skeletal muscle atrophy and paralysis, 
and leads to death in 100% of cases.  Two types of disease onset are seen: limb onset and 
bulbar onset.  Patients with limb onset typically first experience symptoms in their arms 
and legs, often having difficulty running, frequently tripping or stumbling.  In the case of 
bulbar onset, patients first notice loss of motor control in the mouth and may have 
difficulty speaking or swallowing.  In either case, progressive muscle weakness 
eventually spreads to the trunk, where patients have difficulty eating and breathing, 
ultimately needing a ventilator to survive.  Most often death occurs within 2-5 years of 
diagnosis, typically due to respiratory failure (83). 
It is estimated that 30,000 Americans have ALS and on average 15 new cases are 
diagnosed every day (3).  The average age at diagnosis is ~59 years (83), and highest 
prevalence rates are between the ages of 70-79 (103).  ALS is approximately 1.56 times 
more common in males than in females, and it is twice as prevalent in Caucasians than in 
African Americans (103).  
Because there is vast variability of symptoms in the early stages of the disease, 
time from symptom onset to diagnosis is often long (nearly 1 year on average) and 
alternative diagnoses are frequently given prior to ALS diagnoses (109, 134).   To elicit 
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an ALS diagnosis, progressive muscle weakness and degeneration must be observed 
clinically in both the upper motor neurons (UMNs) and lower motor neurons (LMNs).  
Electromyographic needle examination is typically used to assess denervation in LMNs, 
but detecting UMN involvement in the early stages of the disease is more difficult.  ALS 
can only be definitively determined at autopsy (23).  Clinically, ALS is markedly 
heterogeneous.  Even family members with the same gene mutation show differences in 
site of onset, the degree of involvement of UMNs and LMNs, rate of progression, and 
cognitive impairments (131). 
ALS has no cure.  There is one FDA-approved drug for treating ALS, Riluzole, 
which increases lifespan by approximately 3 months (104).  Over 100 compounds have 
been tested for the treatment of ALS, many of which were successful in mice, but none of 
which were effective in humans (64).  Stem cell therapies for ALS are currently being 
investigated.  Although this research is still in the early stages, findings from mouse 
models appear promising and Phase I and II clinical trials are currently underway (101).   
Exercise as a therapeutic intervention has been studied extensively in ALS mice 
and a limited number of studies have been conducted in humans.  Although results are 
mixed, it appears that moderate intensity exercise has a positive impact on symptom 
onset (140), progression (26), and longevity in mice (76), while high intensity exercise 
may be harmful (98).  Light muscle exercise in individuals with ALS resulted in slight 
improvements in function and quality of life (19, 39, 47).  Nevertheless, physicians are 
often hesitant to recommend exercise for individuals with ALS, possibly due to the mixed 
results in the murine literature and a potential link between competitive sports and 
development of ALS (31, 54, 121).  Current treatments for ALS patients focus on 
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maintaining independence, increasing quality of life and prolonging survival.  
Multidisciplinary care (133) and ventilatory support (22) have both been shown to 
increase survival of ALS patients.    
Healthcare costs for ALS patients are high and increase significantly as the 
disease progresses.  Due to the relentlessly fast progression of the disease, ALS patients 
are often unable to work within a rather short timeframe of being diagnosed and require 
fulltime caregivers.  Insurance companies may cover some costs, but coverage is not 
consistent.  Sources of costs include medications to help manage symptoms and reduce 
pain, non-invasive ventilators and mechanical ventilators, and frequent emergency room 
and office visits (105). 
About 5-10% of ALS cases are inherited, frequently as an autosomal dominant 
trait (familial ALS; fALS), however, most cases are sporadic (sporadic ALS; sALS) and 
the cause is unknown. Genetic predispositions, exposure to toxins, and trauma may play a 
role in some cases of ALS.  Early epidemiological studies showed a relationship between 
previous participation in competitive sports and ALS incidence (54).  These findings 
were corroborated by more recent studies, in which incidence of motor neuron disease 
was 1.7 times higher in patients who were varsity athletes compared to those who were 
not (121), and increased incidence of ALS among Italian soccer players (31).  However, 
other studies failed to show an association between competitive sports or sports related 
traumas and development of ALS (135), hence, the relationship between competitive 
sports and ALS development remains unclear.  
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Nearly 25 years ago, researchers identified a close genetic linkage between fALS 
and a gene that encodes a copper zinc-binding superoxide dismutase (SOD1). The 
discovery that ~20% of individuals with fALS have a mutation on the SOD1 gene (118) 
led to the development of an ALS mouse model in which the mutant human SOD1 gene 
is overexpressed (69), the most common of which is the G93A SOD1 mouse model.  
These mice mimic many symptoms seen in ALS, including motor neuron degeneration, 
hind limb weakness and atrophy, which eventually progresses to complete paralysis. 
Since the discovery of SOD1, many other genes associated with ALS have been 
identified.  The most common ALS-linked genes include: transactive response DNA-
binding protein of 43 kilo Daltons (TARDP) (6), fused in sarcolemma/ translated in 
sarcoma (FUS/TLS) (85), and chromosome 9 open reading frame 72 (C9orf72) (43).  
Many of these proteins are primary constituents of neuronal cytoplasmic protein 
aggregates, characteristic of dying neurons in individuals with ALS. 
ALS pathophysiology is complicated, and involves multiple organelles.  Theories 
proposed to explain the underlying pathophysiology include oxidative stress, impaired 
calcium (Ca2+) signaling, mitochondrial dysfunction, protein misfolding and glutamate 
toxicity (20, 132).  The sarco/endoplasmic reticulum (SR/ER) and mitochondria have 
recently been receiving growing attention in ALS pathophysiology.  The endoplasmic 
reticulum (ER) is a site of Ca2+ storage and release, and is involved in protein synthesis 
and facilitation of protein folding (15).  During times of cellular stress—such as when 
there is an accumulation of reactive oxygen species (ROS)— proteins may be improperly 
folded in the ER, leading to an unfolded protein response (UPR) (77).  Misfolded proteins 
can accumulate in the ER, inducing ER stress-signaling pathways that result in alterations 
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in protein expression.  Proteins that enhance cell survival may be up-regulated in an 
attempt to regain homeostasis (e.g. 78 kDa glucose- regulated protein/ binding 
immunoglobulin protein [Grp78/BiP]), or in cases of severe stress proteins involved in 
apoptotic pathways (e.g. C/EBP homologous protein [CHOP]) may be up-regulated.  The 
accumulation of misfolded proteins can also cause misregulated Ca2+ release or uptake in 
the ER (15).  Impaired Ca2+ regulation, ROS, and accumulation of misfolded proteins are 
all involved in ALS pathology.  G93A SOD1 ALS mice show increased intracellular Ca2+ 
in single muscle fibers, potentially due to decreased Ca2+ clearance proteins, 
sarco/endoplasmic reticulum-ATPases (SERCA1 and SERCA2) (28). The SOD1 
mutation results in increased production of the hydroxyl radical, which has been shown to 
inhibit SERCA protein function (149).  Given the role of SERCA1 in Ca2+ regulation, it is 
not surprising that ROS production is also linked to altered Ca2+ regulation (15).  
Movement of Ca2+ from the SR/ER lumen into the mitochondria also stimulates ROS 
production and can induce apoptosis.  Conversely, mitochondrial ROS leaks into the ER 
and affects Ca2+ release channels, creating bidirectional transmission of information 
between the ER and the mitochondria (15). 
Although protein alterations have been studied extensively in human ALS 
neurons, few studies have investigated altered proteins in human ALS skeletal muscle.  
Studies that have been conducted in human skeletal muscle show alterations between 
ALS and control muscle in proteins involved in protein synthesis and atrophy (90, 150), 
trophic factors (96), and the Ca2+ regulatory protein STIM1 (66). 
 Recent work in Dr. Chin’s lab identified differences between ALS and control 
samples in Ca2+ handling and ER stress proteins in G93A*SOD1 ALS mice and between 
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human ALS and disease control skeletal muscle autopsy samples (see Appendix A).  
Specifically, SERCA1, a protein responsible for pumping Ca2+ back into the ER lumen 
after muscle contraction, was significantly decreased in SOD1 mice and in an individual 
with an SOD1 mutation compared to disease control (post-polio) and individuals with a 
C9orf72 mutation.  The ER chaperone protein Grp78/BiP was significantly up-regulated 
in ALS mice compared to control mice, and also tended to be higher in individuals with a 
C9orf72 mutation and sALS compared to individuals with a SOD1 mutation and disease 
control.   
Proteins involved in protein synthesis, such as protein kinase B (Akt), have been 
linked to survival in individuals with ALS (151).  Preliminary data from Dr. Chin’s lab 
support the notion that Akt and the protein synthesis pathway is altered in ALS.  Western 
blot analysis showed reduced Akt protein level in ALS with a C9orf72 mutation but not 
in ALS with a SOD1 mutation (see Appendix B).   Thus, preliminary data suggested that 
protein markers in ALS muscle tissue differ not only between ALS and control cases, but 
also between subgroups of individuals with ALS, depending on the cause of the disease. 
Research Focus and Hypotheses 
This research study investigated whether proteins involved in SR/ER stress, Ca2+ 
handling, and protein synthesis were altered in human ALS skeletal muscle.  Specifically, 
alterations in proteins involved in Ca2+ regulation (SERCA1, SERCA2, parvalbumin 
[PV]), ER stress (protein disulfide isomerase [PDI], Grp78/BiP, CHOP, inositol-requiring 
enzyme 1- alpha [IRE1α]), and protein synthesis (Akt) were assessed between ALS and 
healthy and diseased control human skeletal muscle.  It also investigated Glyceraldehyde 
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3- Phosphate Dehydrogenase (GAPDH), α-actin and β-actin as loading controls.  Results of 
the β-actin loading control experiments led to this protein being investigated as a target 
protein instead of a loading control.  In addition, an exploratory analysis of differences 
within ALS subgroups was conducted (e.g. differing sites of onset, presence/ absence of 
gene mutations).  To this author’s knowledge, no studies have investigated differences in 
expression of these proteins in human ALS skeletal muscle, with the exception of Akt.  
Previously, Dr. Chin’s lab identified alterations in SERCA1, SERCA2, PV, PDI, 
Grp78/BiP, CHOP, IRE1α, and Akt in the common mouse model of ALS.  Based on 
these findings, it was hypothesized that SERCA1, SERCA2, and PV levels would be 
lower in ALS and PDI, Grp78/BiP, CHOP, IRE1α, and Akt levels would be higher in 
ALS compared to healthy controls. 
Specific Aims  
Specific Aim 1: to optimize the protein quantification assay (western blot technique) for 
assessment of SERCA1, SERCA2, PV, PDI, Grp78/BiP, CHOP, IRE1α, Akt, and β-actin 
in human skeletal muscle samples. 
Specific Aim 2: to quantify differences in muscle protein levels of SERCA1, SERCA2, 
PV, PDI, Grp78/BiP, CHOP, IRE1α, Akt and β-actin in skeletal muscle samples from 
ALS cases compared to disease and healthy controls. 
Specific Aim 3: to conduct exploratory analyses of differences in muscle protein levels of 
SERCA1, SERCA2, PV, PDI, Grp78/BiP, CHOP, IRE1α, Akt, and β-actin between 
subsets of ALS cases (i.e. limb onset vs. bulbar onset; sALS vs. fALS). 
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Chapter 2: Methods 
Autopsy skeletal muscle samples from ALS, healthy controls, and disease 
controls were analyzed via western blot.  ALS samples included sALS, fALS, samples 
with a C9orf72 mutation, and one sample with a SOD1 mutation.  Additionally, muscle 
samples were from individuals with limb and bulbar onset, and taken from several 
different muscles. Samples were probed for SERCA1, SERCA2, PV, PDI, Grp78/BiP, 
CHOP, IRE1α, Akt, and β-actin and protein levels quantified by chemiluminescence.  
Differences in protein levels of each target protein were analyzed between ALS and 
controls.  Exploratory analyses were conducted between ALS subgroups. 
Muscle Samples  
Sixty-three muscle autopsy samples from 47 cases, including ALS of varying subtypes 
(sALS, fALS, C9orf72), healthy controls (CON), and disease controls were analyzed.  
Banked skeletal muscle samples from autopsy were obtained from Dr. Lyle Ostrow and 
Dr. Justin Kwan. Dr. Chin has an IRB Exemption category #4 letter (Project #404343-1) 
for the “Analysis of human skeletal muscle biopsy samples for ALS biomarkers” which 
covers this project (Appendix O). Disease controls were spinal muscle atrophy (SMA) 
cases; because these were not age-matched to ALS and healthy control cases, a control 
SMA (CON-SMA) group that was age matched to the SMA samples was also included.   
Study blinding  
The researcher conducting analyses was blind to sample identities during immunoblotting 
and quantification of target proteins (see Appendix B).  After quantification was 
completed, Dr. Chin un-blinded the data for analyses. 
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Tissue Homogenization   
Muscle samples were stored at -80°C prior to use.  During the homogenization process 
samples were stored in liquid nitrogen until just before homogenization took place.  
Samples were transferred from liquid nitrogen directly to a tube that contained chilled 
RIPA buffer (0.15M NaCl, 0.01M Tris-HCl pH 8, 0.005M EDTA, 0.5% Sodium 
Deoxycholate, 0.1% SDS, 1% Triton-X100, and Roche protease inhibitor cocktail tablet 
REF# 11836170001) on ice.  Dr. Chin’s lab previously conducted an experiment 
comparing buffers for homogenization of human skeletal muscle, and determined the 
RIPA buffer produced the best results with human muscle tissue.  The muscle sample/ 
RIPA buffer combination remained on ice throughout the entire homogenization process.  
The muscle tissue was minced with sterile lab scissors and further homogenized with a 
polytron for 3 x 10sec (~ 30 seconds total).  Homogenates were then spun at 4oC for 10 
minutes at 14000 rpm (20000 RCF). Soluble protein (i.e., the supernatant) was extracted 
with a micropipette.   
Determination of Protein Concentration   
Protein concentration of lysates was determined by the bicinchoninic acid (BCA) assay 
(Thermo Scientific BCA Assay Protocol).  Briefly, a serial dilution of bovine serum 
albumin (BSA) was loaded in triplicates into a 96-well plate, along with triplicates of 
each sample lysate and a triplicate of diluted RIPA buffer (25µl of each/well).  BCA 
reagents were combined (1 part reagent B: 50 parts reagent A) and 200µl of the combined 
reagents was added to each well utilizing a multi-tip pipette.   The 96-well plate was 
incubated at 37°C for 30 minutes on a rotary platform then analyzed with a 
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spectrophotometer.   Sample lysates of unknown protein concentrations were compared 
to the BSA standard (known protein concentration) and protein concentrations of the 
sample lysates were extrapolated. 
Sample Preparation 
To prepare samples for electrophoresis, equal amounts of total protein (as determined by 
BCA assay) of each sample was combined with Bio-Rad Laemmli 2x Loading Buffer and 
boiled at 100°C for 5 minutes.  Samples were then chilled on ice and stored at 4°C until 
ready for use. 
Electrophoresis  
Equal amounts of total protein (approximately 14µg) of each sample was loaded into Bio-
Rad Mini-Protean TGX precast gels along with a molecular weight marker (Bio-Rad 
Precision Plus Dual Xtra Protein Standard).  
Gels were electrophoresed at 175V for various lengths of time, depending on the 
molecular weight of the target protein.  After electrophoresis, proteins were transferred to 
a polyvinyladine fluoride (PVDF) membrane using Bio-Rad Trans Blot ® Turbo Transfer 
packs and the Bio-Rad Trans Blot ® Turbo Transfer system.  Membranes were then 
blocked in 3% BSA for 1 hour at room temperature on a rotary platform.   
Immunoblotting and Target Protein Detection 
Membranes were incubated in primary antibodies against target proteins (SERCA1, 
SERCA2, PV, PDI, Grp78/BiP, CHOP, IRE1α, Akt, and β-actin) overnight at 4°C on a 
rotary platform.  See Table 1 for antibody vendors and dilutions. The following day, 
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membranes were washed in 1x TBST 3 times for 10 minutes each at room temperature.  
Membranes were then incubated in the appropriate secondary antibody (see Table 1) for 
1 hour at room temperature, followed by 3 x 10 minute 1x TBST washes at room 
temperature.  Membranes were incubated in Bio-Rad Clarity Electrochemiluminescence 
(ECL) substrate for 4 minutes, and then exposed using the Bio-Rad Chemidoc MP 
equipment. If weak or no signal was detected from target bands, the membrane was 
immediately incubated in Thermo Scientific SuperSignal ® West Dura Extended 
Duration Substrate and re-imaged. 
Table 1.  Antibody vendors and dilutions 
  Antibody Vendor Catalog Number Dilution Secondary 
SERCA1 CST 12293s 1:1000 Rabbit 
SERCA2 CST 9580s 1:1000 Rabbit 
PV Swant pvg-214 1:1000 Goat 
PDI CST 2446s 1:1000 Rabbit 
Grp78/BiP CST 3177p 1:1000 Rabbit 
CHOP CST 2895s 1:1000 Mouse 
IRE1α CST 3294 1:1000 Rabbit 
Akt CST 4685s 1:1000 Rabbit 
β-actin Santa Cruz 47778 1:1000 Mouse 
GAPDH Thermo Scientific MA5-15738-BTLN 1:1000 Mouse 
α-actin (Acta1) Protein Tech Group C7521 1:1000 Rabbit 
Anti-goat Novus NB710-H 1:1000 N/A 
Anti-mouse CST 7076s 1:1000 N/A 
Anti-rabbit CST 7074s 1:1000 N/A 
 
In some cases, membranes were stripped and re-probed for a different target 
protein.  In these cases, membranes were incubated in strip buffer (0.1M BME, 2% SDS, 
and .06M Tris-HCl pH 6.8) for 30 minutes at 60°C, washed in 1x TBST (2 x 15 minutes 
each followed by 2 x 5 minutes each), and incubated in a different primary antibody 
(overnight at 4°C, followed by the same procedure previously detailed).  
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Target Protein Identification and Quantification 
Target proteins were identified by comparison to a protein standard with known 
molecular weight markers run on the gel (Bio-Rad Precision Plus Protein Dual Xtra 
Protein Standard). Using Bio-Rad Image Lab 5.0 software, images of the molecular 
weight marker were taken under the Alexa setting and overlaid with chemiluminescent 
images (Appendix C).  Target chemiluminescent bands were identified according to 
molecular weight.  Target proteins were then quantified for volume intensity with Bio-
Rad quantitation analysis tools (Image Lab Software 5.0). 
Loading Control  
Total protein was selected as a loading control (see loading control experiments under 
Condition Optimization Experiments section below).  Membranes were stained for total 
protein with Thermo Scientific Memcode PVDF stain (according to Thermo Scientific 
protocol).  Membranes were then imaged with the Bio-Rad Chemidoc MP equipment and 
total protein signal quantified for volume intensity with Bio-Rad Image Lab software. 
Condition Optimization Experiments 
The lab recently acquired a new system (Bio-Rad Trans-Blot ® Turbo Transfer System) 
for transferring protein to PVDF membranes.  Hence, it was necessary to optimize 
Western Blot conditions to the new system.  Several preliminary experiments were run to 
determine optimal loading volumes of proteins, SDS-PAGE gel percentages, transfer 
times, and a reliable loading control.    
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Transfer times.  To assess the optimal length of time for transferring proteins from SDS-
PAGE gels to PVDF membranes, different transfer times were tested, and two PVDF 
membranes were placed back to back to determine if any proteins were being over-
transferred.  After transfer, gels and membranes were visualized to determine the amount 
of protein that was transferred to the PVDF membrane, if any protein still remained on 
the gel, and if any protein was over-transferred through the first PVDF membrane onto 
the second membrane.    
Percentage of SDS-PAGE gel.  Determination of the optimal percentage of SDS-PAGE 
gel to use was primarily trial and error.  Initial western blots utilized the percentage gel 
recommended by Bio-Rad according to the molecular weight of the target protein.  This 
percentage was adjusted depending on quality of the western blot results. 
“Housekeeping gene” loading control determination.  Multiple loading controls that 
are frequently used in the literature were tested, including GAPDH, β-actin, α-actin, and 
total protein.  In many cases, the same membrane was probed for different loading 
controls, and quantification of bands from the same membrane were compared.  Bio-Rad 
stain-free gels were tested, with the hope of using total protein on the PVDF membrane 
visualized with the stain free technique as a loading control.  With the stain free 
technique, gels contain trihalo compounds that react with tryptophan residues in proteins 
and can be visualized on gels or PVDF membranes, yielding an image of the total 
protein.  Total protein was also visualized using Memcode Stain for PVDF membranes 
(Thermo Scientific).   
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Linearity of chemiluminescent signal.  To determine if chemiluminescent signal 
increased linearly with increasing protein amount, western blots were conducted in which 
a range of total protein was loaded across a gel, and chemiluminescent signal in each lane 
was quantified.   Specifically, 6-20µg of protein of the same sample was loaded across 
lanes and western blot was carried out as usual.  Signal of the target bands were then 
quantified and graphed to determine if chemiluminescent signal increased linearly with 
increasing protein.  This was done for four different samples: one that previously showed 
high signal for Grp78/BiP and one that showed low signal for Grp78/BiP, as well as two 
others that showed high/ low signal for SERCA1.   Linear regression analyses were 
completed to look at linearity of chemiluminescent response. 
Statistical Analysis 
One-way between subjects analysis of variance (ANOVA) with least significant 
difference (LSD) post hoc analyses (when appropriate) was used to compare protein 
levels of each target protein between groups.  In some instances, t-tests were used to 
assess the difference in protein levels between two groups. Except when indicated 
otherwise, results reported are one-way between-subjects ANOVA (number of cases [n], 
mean [M], standard deviation [SD]). Additionally, because a shift from type II to type I 
muscle fibers has been observed in ALS, the ratio of SERCA2 to SERCA1 protein levels was 
also compared between groups.  A p value of < 0.05 was considered significant.  Group 
comparisons included: 
• Different disease groups (all samples): ALS, healthy controls (CON), 
SMA, and controls age matched to SMA (CON-SMA) 
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o Different disease groups using only psoas muscles 
• Cases with confirmed C9orf72 mutation present vs. absent 
• Cases with known familial history of ALS (fALS) vs. those known to lack 
a familial history (sALS) 
• Limb vs. bulbar onset 
• Analyses of samples from specific muscles:  
o Quadriceps muscle vs. biceps muscle from the same individual 
with ALS 
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Chapter 3: Results 
Method for Identifying Target Proteins 
Utilizing Bio-Rad Image Lab software, chemiluminescent images showing antibody –
protein signals and Alexa images showing protein marker (Bio-Rad Dual Xtra) with 
bands of known molecular weight were superimposed (see Appendix C).  Target bands 
were then identified according to expected molecular weight and the molecular weight 
standard. 
Condition Optimization 
Timing of PVDF transfer.  The Bio-Rad preset transfer setting “turbo” was ideal 
for most target proteins (see Appendix D).  Under this setting, the majority of proteins 
below 100 kDa were transferred from the SDS-PAGE gel to the PVDF membrane, and 
over-transfer was minimal.  For higher molecular weight proteins such as SERCA1 and 
SERCA1, the “high molecular weight” preset setting was used.   
Percentage of SDS-PAGE gel.  Both 10% and 12% Bio-Rad Mini-Protean TGX 
pre-stained, precast gel produced quality results (see Appendix E).  In some instances, 
7.5% gels appeared to produce diffuse target bands, thus only 10% and 12% gels were 
used.   
 “Housekeeping gene” loading control determination.  Different endpoints were 
investigated as a loading control (see Appendix F).  GAPDH, β-actin and α-actin 
(specifically, Acta1) showed much variability across lanes, and were thus determined to 
be unreliable as loading controls.  After observing β-actin variability, the decision was 
	   17	  
made to include β-actin as a target protein to determine if there were certain groups (or 
muscles) that tended to show higher or lower protein levels.  
Bio-Rad stain free gels were tested to determine total protein, however, results 
showed very weak signal and high background.  Total protein visualized with Memcode 
PVDF stain provided the clearest visualization of total protein and was determined to be 
the best loading control option.  Total protein signal for each entire lane was quantified 
with Image Lab Software and the coefficient of variation for each membrane was 
determined.  Only those membranes with coefficients of variation less than 20% were 
considered acceptable.   
Linearity of chemiluminescent signal and quantity of protein loaded per lane.  
After the optimizations above were completed, the linearity of response of the 
chemiluminescent signal with increased total protein load was evaluated for linearity as a 
way to determine whether differences between samples and between subject groups fell 
within the linear range of this assay.  Chemiluminescent signal increased linearly with 
increasing amount of protein at both the lower range of signal and higher range of signal 
for both SERCA1 and Grp78/BiP.  It is possible that signal may drop off at extremely 
high protein values (see Figure 1A and 1B). Alternatively, the observed results could 
have been due to less than the desired amount of protein (20µg) loaded into these lanes 
due to the small size of the wells (i.e., some of the sample may have “spilled over” and 
not stayed within the well).  These results were also utilized to determine the optimal 
amount of protein to load into the gels.   Due to the decrease in signal observed at 20µg, it 
was determined that less than this amount was optimal.  Because signal appeared linear 
between 6-18µg of protein,   ~14µg of protein per lane was chosen—an amount that was 
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thought to balance between effects of pipetting error (which would be more prominent at 
very low amounts of protein) and conservation of samples (loading higher amounts of 
protein would require more of the muscle tissue, perhaps unnecessarily).   
 
 
Figure 1.  Graphs of chemiluminescent signal for SERCA1 (A and B) and Grp78/BiP (C and D) 
for a range of total protein concentrations, with raw chemiluminescent image depicted below each 
graph.  Samples with very low signal for the target protein are shown on the left (A and C), while 
samples with high signal for the target protein are shown on the right (B and D).  X-axis values 
are µg of total protein loaded in each lane; y-axis values are protein signal (AU x 106).  Blue lines 
indicate signal of target protein; black lines indicate a linear regression.  Equations for regression 
lines and R2 are shown above the lines.  
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Western Blot Results 
Target bands for PV and IRE1α could not be confidently identified.  Membranes for these 
proteins contained significant amounts of non-specific binding, and no clear bands at the 
target molecular weight of these proteins could be identified (Appendix G shows results 
for IRE1α).  Hence, these two proteins were excluded from the study.    
Differences in protein levels between disease and control groups. 
Levels of Akt, Grp78/BiP, CHOP, and β-actin, were significantly different between 
disease groups, while SERCA1, SERCA2, and PDI levels were not significantly different 
between groups (see Appendix H). 
Akt.  One-way between-subjects ANOVA conducted between ALS, CON, SMA, 
and CON-SMA revealed a significant effect of disease group on Akt protein level (p =  
0.02).  LSD post hoc comparisons indicated that mean protein level for the ALS group (n 
= 38, M = 94,261,937, SD = 62,180,996) was significantly higher than mean protein level 
for the CON group  (n = 13, M = 43,353,982, SD =  47,917,747; p = 0.007).  Mean 
protein level for the SMA group (n = 7, M = 117,595,063, SD = 36,943,467) was also 
significantly higher than the control group (p = 0.007; Figure 2).  The CON-SMA group 
(n = 3) was not significantly different from any other groups. 
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Figure 2. Average Akt levels from western blot analyses for the 4 disease groups.  Akt protein 
level was significantly higher in ALS and SMA skeletal muscle compared to CON.  Data shown 
are mean protein levels (AU x 106) + standard error (SE).  *Indicates significant difference from 
CON, p < 0.05.  
Grp78/BiP.  Analyses also revealed a significant effect of disease group on 
Grp78/BiP protein level between the four groups (p = 0.034).  Post hoc comparisons 
indicated that mean protein level for the ALS group (n = 39, M = 51,634,409, SD = 
41,020,106) was significantly higher than mean protein for the CON group (n = 13, M = 
14,483,527, SD = 19,883,948; p = 0.005; Figure 3).  The CON-SMA group (n = 3) and 
SMA group (n = 5) were not significantly different from any other groups. 
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Figure 3.  Grp78/BiP western blot results showing protein levels for different disease groups.  
Grp78/BiP chemiluminescent image is shown with total protein below demonstrating equal 
loading across lanes (A).  Bar graph (B) shows mean protein levels (AU x 106) + SE for each 
group.  *Indicates significant difference from CON, p < 0.05.  
CHOP.  Significant differences were seen for CHOP protein levels between 
groups (p = 0.029).  ALS was not different from CON, but ALS had significantly higher 
protein levels (n = 38, M = 95,146,570, SD = 62,225,605) than SMA (n = 6, M = 
41,525,999, SD = 41,799,636; p = 0.036) and CON-SMA (n = 3, M = 13,152,370, SD = 
17,349,400; p = 0.019; Figure 4).  The CON group (n = 12) was not significantly 
different from any other groups. 
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Figure 4.  CHOP western blot results showing protein levels for different disease groups.  CHOP 
chemiluminescent image is shown with total protein below demonstrating equal loading across 
lanes (A).  Bar graph (B) shows mean protein levels (AU x 106) + SE for each group.  # Indicates 
significant difference from ALS, p < 0.05.  
β-actin.  There was also a significant effect of disease group on β-actin protein 
levels (Figure 5) between the four groups.  Specifically, protein levels in the CON group 
(n = 13, M = 28,556,806, SD = 42,686,415) and ALS group (n = 38, M = 50,856,808, SD 
= 63,639,054) were significantly lower than protein levels in the SMA (n = 7, M = 
111,434,993, SD = 64,084,267; p = 0.005 vs. CON; p = 0.018 vs. ALS) and CON-SMA 
(n = 3, M = 125,095,703, SD = 75,905,545; p = 0.015 vs. CON; p = 0.045 vs. ALS) 
groups.   
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Figure 5.  β-actin western blot results showing protein levels for different disease groups.  β-
actin chemiluminescent image is shown with total protein below demonstrating equal loading 
across lanes (A).  Bar graph (B) shows mean protein levels (AU x 106) + SE for each group. 
*Indicates significant difference from CON, p < 0.05.  # Indicates significant difference from 
ALS, p < 0.05.  
SERCA2, SERCA1 and PDI.  ANOVA indicated there was not a significant 
effect of disease group on SERCA2 (Figure 6A), SERCA1 (Figure 6B), or PDI (Figure 
6C) protein levels between the four groups. 




Figure 6. Western blot results for SERCA2 (A), SERCA1 (B) and PDI (C) protein levels in 
different disease groups.  Chemiluminescent images for SERCA2 (A) and PDI (C) are shown 
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with total protein below demonstrating equal loading across lanes.  Bar graphs for each target 
protein show mean protein levels (AU x 106) + SE for each group.  
 SERCA2/SERCA1 ratio.  Although no significant differences were found 
between ALS and CON in SERCA1 or SERCA2 levels, t-test revealed the 
SERCA2/SERCA1 ratio was significantly higher in ALS (n = 38, M = 13.87, SD = 
21.46) compared to CON (n = 13, M = 3.89, SD = 2.79; p = 0.008; Figure 7B).  Levene’s 
test for equality of variances between ALS and CON for SERCA2/SERCA1 ratio was 
significant (p = 0.012; Appendix I), indicating a significant difference in variance of 
SERCA2/SERCA1 ratio between ALS and CON (see Figure 8 for scatterplot of 
SERCA2/SERCA1 ratios for ALS and CON).  Hence, the t-test results for equal 
variances not assumed were considered (and were significant).  Additional t-tests were 
conducted in an effort to identify a potential source of the greater variability seen in the 
SERCA2/SERCA1 ratio in ALS.  T-tests revealed the SERCA2/SERCA1 ratio was 
significantly higher in diaphragm muscles (n = 3, M = 12.55, SD = 1.27) compared to 
quadriceps muscles (n = 7, M = 1.48, SD = 1.43; p < 0.001; Figure 13A) in ALS. No 
significant differences in SERCA2/SERCA1 ratio were found between sites of disease 
onset, or congruence/ incongruence between site of onset and muscle (e.g. limb onset and 
psoas muscle considered congruent, bulbar onset and psoas muscle considered 
incongruent). 
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Figure 7.  Bar graph showing SERCA1 and SERCA2 levels in ALS and CON (A) and SERCA2/ 
SERCA1 ratio for ALS and CON (B). Values shown in A are mean protein levels (AU x 106) + 
SE. *Indicates significant difference from CON, p< 0.05. 
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Figure 8.  Scatterplot of SERCA2/SERCA1 ratio for CON and ALS cases. 
Analyses of differences in protein levels between disease groups for psoas 
muscles only.  Due to the different muscles obtained for the CON and ALS cases and the 
concern that there could have been differences in protein levels between the different 
muscles, separate analyses were completed on a sub-set of cases where psoas muscle was 
available (Appendix K).  T-tests conducted between CON and ALS for psoas muscles 
showed that Grp78/BiP was significantly higher in ALS (n = 6, M = 76,927,621, SD = 
57,326,843) compared to CON (n = 13, M = 14,483,527, SD = 19,883,947, p = 0.044; 
Figure 9).  CHOP protein levels were also significantly higher in ALS (n = 6, M = 
135,170,418, SD = 63,426,144) compared to CON (n = 12, M = 74,113,150, SD = 
47,347,041, p = 0.035; Figure 9) psoas muscles.  The CON-SMA group only contained 
one psoas muscle, so this group was not included in these analyses.   Two of the 3 SMA 
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psoas samples were on the same membrane and potentially skewed, hence, this data was 
excluded from these analyses (see discussion). 
Similar trends in protein levels for ALS and CON groups were observed when 
including all muscles vs. only the psoas muscle.  The degree of differences in protein 
levels between ALS and CON did vary between all muscles vs. only the psoas muscles in 
some cases, but differences were always in the same direction regardless of muscle 
group.  With the exception of PDI—which showed low signal and little variability across 
all samples— differences in protein levels between ALS and CON were in the 
hypothesized directions.  Figure 9A shows differences in protein for each target protein 
between ALS and CON samples for all muscles.  As hypothesized, levels of Akt and 
Grp78/BiP were significantly higher in ALS compared to CON.  Although not 
statistically significant, differences in expression of SERCA1, SERCA2, and CHOP were 
in the predicted directions.  SERCA1 expression was ~40% lower in ALS than in CON. 
Expression of CHOP was 22% higher in ALS compared to CON.  As shown in figure 9B, 
similar trends were observed when only the psoas muscle was included in analyses. 
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Figure 9.  Bar graphs showing mean protein levels (AU x 106)  + SE for each target protein in 
ALS and CON samples for all muscles combined (A) and only psoas muscles (B).  *Indicates 
significant difference from CON, p < 0.05.   
Differences in protein levels in C9orf72 cases.  ANOVA in target protein levels 
between ALS cases that had a C9orf72 mutation (defined clinically as a GGGGCC repeat 
expansion of  > 30; +C9orf72; n = 7), ALS cases that were confirmed to lack a C9orf72 
mutation (30 or less repeat expansions; - C9orf72; n = 13), and CON samples (n = 13) 
revealed significant differences between these three groups (Figure 10; Appendix L) in 
levels of SERCA1 (p = 0.022), and Grp78/BiP (p = 0.015).  Specifically, SERCA1 was 
significantly higher in CON (M = 79,243,663, SD = 73,560,886) than in + C9orf72 (M = 
13,175,395, SD = 11,620,125; p = 0.016) and – C9orf72 (M = 27,433,424, SD = 
46,187,598; p = 0.023; Figure 10A and 10C) and Grp78/BiP was significantly lower in 
CON (M = 14,483,527, SD = 19,883,948) compared to + C9orf72 (M =52,020,565, SD 
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=37,976,519; p = 0.031) and – C9orf72 (M =54,622,042, SD = 44,734,804; p = 0.007; 
Figure 10B and 10C).  No significant differences were found in any other target proteins 
between + C9orf72, - C9orf72, and CON groups. 
	  
Figure 10.  Western blot results for SERCA1 (A) and Grp78/BiP (B) in cases that had a C9orf72 
mutation (+), cases that did not have a C9orf72 mutation (-), and CON.  Chemiluminescent image 
for SERCA1 and Grp78/BiP is shown with image of total protein stain below demonstrating 
equal loading across lanes.  Panel C shows mean protein signal (AU x 106 + SE) of SERCA1 and 
Grp78/BiP for the three groups.  *Indicates significant difference from CON, p < 0.05.   
Differences in protein levels between sALS and fALS.  There was a significant 
effect of group on SERCA1 (p = 0.025) and Grp78/BiP (p = .004) protein levels between 
cases with a known familial linkage (fALS), those that were known to lack a familial 
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linkage (sALS) and CON (Figure 11; Appendix M).  Post hoc analyses revealed that 
mean SERCA1 levels in the fALS (n = 3, M = 6,556,413, SD = 5,035,731), and sALS (n 
= 17, M = 26,360,052, SD = 40,920,870) groups were significantly higher than mean 
protein levels in the CON group (n = 13, M = 79,243,663, SD = 73,560,886; p = 0.049 
vs. fALS; p = 0.014 vs. sALS).  Grp78/BiP was significantly higher in the sALS group (n 
= 18, M = 63,994,984, SD = 46,540,662,) compared to the CON group (n = 13, M = 
14,483,527, SD = 19,883,948, p < 0.001).  No significant differences in any target 
proteins were found between the fALS and sALS groups.   
 
Figure 11.  Bar graph showing mean SERCA1 and Grp78/BiP protein levels in sALS, fALS and 
CON.  Data shown are mean protein levels  (AU x 106) + SE.   *Indicates significant difference 
from CON, p < 0.05.   
Differences in target protein levels in limb vs. bulbar onset.  There were 
significant differences between groups in Akt (p = 0.027), β-actin (p = 0.025), and 
Grp78/BiP (p = 0.010) protein levels between limb onset, bulbar onset, and CON (Figure 
12; Appendix N).  Specifically, Akt and Grp78/BiP protein levels were significantly 
higher in bulbar (Akt n = 12, M =  101,777,107, SD = 52,314,906, p = 0.017; Grp78/BiP 
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n = 13, M = 58,747,807, SD = 47,405,522, p = 0.004) and limb (n = 25; Akt M =  
93,481,494, SD = 66,853,987, p = 0.017; Grp78/BiP M = 47,534,620, SD = 38,619,318, 
p = 0.013) onset compared to CON (n = 13; Akt M = 43,353,982, SD = 47,917,747; 
Grp78/BiP M = 14483527, SD = 19883948); β-actin expression was significantly higher 
in limb onset (n = 25, M = 62,736,136, SD = 66,491,068) compared to bulbar onset (n = 
12, M = 14,112,736, SD = 17,299,646, p = 0.012).  Although not statistically significant 
(p = 0.071), expression of SERCA1 was 59% higher in CON than in bulbar (Figure 12). 
 
Figure 12.  Western blot results showing differences in mean protein levels of all target proteins 
between limb onset, bulbar onset, and CON.  Raw chemiluminescent western blot images for Akt 
(A) and β-actin (B) are shown with total protein image below showing equal loading across lanes.  
Data shown in C are mean protein levels  (AU x 106) + SE.   *Indicates significant difference 
from CON, p < 0.05.   ^ Indicates significant difference from bulbar, p < 0.05.   
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Differences in protein levels in different muscles.  ANOVA showed no significant 
effect of muscle source (psoas, quadriceps, diaphragm, biceps and intercostals were 
included; see Table 3 for n of each muscle) on level of any target proteins in the ALS 
group.  However, independent samples t-tests revealed that SERCA1, Grp78/BiP, CHOP, 
and the SERCA1/SERCA2 ratio (previously discussed) levels were significantly different 
in ALS diaphragm muscles compared to quadriceps muscles (Appendix J).  Specifically, 
SERCA1 was significantly lower in diaphragm muscles (M = 9185196, SD = 3360297) 
compared to quad muscles (M = 95500456.57, SD = 75348323.22, p = 0.023), and 
Grp78/BiP and CHOP were significantly higher in diaphragm muscles (Grp78/BiP M = 
79,825,420, SD = 45,631,721; CHOP M = 103860866, SD = 31070804) compared to 
quadriceps muscles (Grp78/BiP M = 28779310, SD = 22110883, p = 0.038; CHOP M = 
50441546, SD = 23977617, p = 0.017).    
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Figure 13.  Mean SERCA2/SERCA1 ratio (A) and protein levels for Grp78/BiP, CHOP, and 
SERCA1 (B) in quadriceps and diaphragm muscles of ALS.  Data shown are mean (A) ratio and 
(B) protein levels  (AU x 106) + SE.   * Indicates significant difference from diaphragm, p < 0.05.   	  
ALS biceps (n = 7) and ALS quadriceps (n = 7) muscles were also analyzed 
separately since there was one of each muscle type from the same individual (for 7 
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Table 2.  Location of muscle samples for each disease/ control group 
Muscle CON ALS 
 CON-
SMA  SMA Total 
Deltoid   2     2 
Psoas 13 6  1  3 23 
Quad   7*     7 
Diaphragm   3  2  4 9 
Bicep   7*     7 
Tongue   1     1 
Intercostals   2     2 
Unknown   11     11 
Total 13 39  3  7 62 
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Chapter 4: Discussion 
 Analysis of skeletal muscle autopsy samples from ALS patients and various 
controls demonstrated that the ER stress protein (Grp78/BiP), and Akt, a protein involved 
in protein synthesis, were higher in ALS compared to CON.  The SERCA2/SERCA1 
ratio was also higher as well as significantly more variable in ALS compared to CON.  
Furthermore, differences in protein levels of SERCA1, Grp78/BiP, and CHOP were 
observed in ALS diaphragm compared to quadriceps muscles.  This study identifies the 
possibility that Ca2+ regulatory proteins, ER stress proteins, and proteins involved in 
protein syntheses are altered in ALS human skeletal muscle, and that different muscles 
may be differentially affected.  
Western Blot Loading Controls with Diseased Muscle 
When utilizing the immunoblotting technique, it is important to ensure equal amounts of 
total protein from each sample are loaded into the SDS-PAGE gel for electrophoresis.  If 
protein loading is not equal, differences detected between samples in target proteins 
could be due to differences in the amount of total protein loaded rather than true 
differences between samples in the amount of the target protein.  To ensure equal 
loading, researchers often probe membranes for “housekeeping” or “loading control” 
proteins—proteins that should be present in equal amounts in samples. The housekeeping 
proteins GAPDH, β- Actin, and α- Actin, commonly used in the literature, were tested in 
this study in order to determine which (if any) were the most reliable.   
  GAPDH showed much variability across samples in the present experiment (see 
Figure A6).  This protein is a glycolytic enzyme that catalyzes the conversion of 
	   37	  
glyceraldehyde-3-phosphate to 1,3-bisphosphoglycerate in the glycolytic pathway.  
Because the glycolytic capacity of type I muscle fibers is low and that of type II fibers is 
high, one would expect higher expression of GAPDH in type II fibers.  ALS mice have 
shown selective denervation of large, type II motor units, while no denervation in the 
smaller, type I motor units was observed.  These mice had significantly less type IIB 
muscle fibers compared to wild type mice (72).  It is plausible that ALS muscle tissue 
would show decreased expression of GAPDH compared to healthy tissue, due to having 
less type II muscle fibers compared to healthy tissue.  If GAPDH was used as a loading 
control in these cases, the quantity of total protein loaded for ALS samples would be 
underestimated compared to healthy tissue.  Glycolytic demands may also differ between 
tissue that is in a normal state compared to a diseased state, contributing further to 
differences in GAPDH expression (10).  Additionally, GAPDH is inactivated by 
particular oxidants (122).  Given the known involvement of reactive oxygen species in 
ALS, it is possible that alterations in oxidant levels could be present in ALS muscle and 
effect GAPDH expression.  GAPDH levels will also differ between the different skeletal 
muscle used and may also be different between individuals.  Hence, there are numerous 
factors that could result in differences in GAPDH levels between ALS and control 
muscle, and its reliability as a housekeeping protein in this population is questionable.  
Although differences in GAPDH protein expression between ALS and control muscles 
were not specifically assessed, the potential for differences between groups based on the 
literature and the variability that was observed in the present experiment between samples 
lead to this protein being excluded as a loading control. 
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The cytoskeletal proteins tubulin and actin are abundant in cells, and therefor 
frequently used as a western blot loading control.  Most often the α or β Tubulin families 
are used, which represent the major components of microtubules in the eukaryotic 
cytoskeleton.  Given its abundance in cells, Tubulin may be a reliable loading control in 
many circumstances, however, recent research has discovered a high occurrence of 
mutation in the gene that encodes an α-tubulin (TUBA4A) in ALS (126).   Similarly, 
alterations in the PFN1 gene, which plays a crucial role in actin dynamics, has also been 
linked to fALS.  PFN1 mutants show reduced expression of F/G-actin (148). Hence, it is 
plausible neither tubulin nor actin are reliable loading controls for ALS samples.   
α- Actin and β-actin were investigated in the present experiment as loading 
controls, and showed much variability between samples (Figure A6).   Indeed, other 
researchers have also shown β-actin is not a reliable loading control in western blots (46, 
50).  After observing β-actin variability, the researchers decided to include β-actin in the 
target protein experiments and analyze data to determine if there were certain conditions 
(or muscles) that tended to show higher or lower levels of this protein.  β-actin was ~4.5 
times higher in limb onset compared to bulbar onset (Figure 12).  Interestingly, this was 
the only significant difference in all of the analyses conducted in which two ALS subsets 
showed differences in protein levels in opposite directions relative to CON samples; β-
actin level in limb onset was over 2 times that of CON, while levels in bulbar onset were 
approximately half that of CON. 
Total protein has recently been established as a reliable loading control for 
western blots (2, 50, 117).  Although others have been successful using the Bio-Rad stain 
free technique to visualize total protein (57), this method resulted in very high 
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background and the inability to accurately quantify total protein signal in the present 
experiment.  Ultimately, total protein visualized with Memcode PVDF stain was selected 
as a loading control.   This method is similar to a Ponceau or Coomassie blue stain, both 
of which have been reported as reliable loading controls for western blots (50, 117).   
Chemiluminescent Signal Increases Linearly With Increasing Amounts of Protein 
It was necessary to characterize the relationship between amount of protein and 
chemiluminescent signal, especially at very high or low ends of the signal range.  For 
example, if chemiluminescent signals began to plateau at high values, a two-fold increase 
in amount of protein would result in a less-than-two fold increase in chemiluminescent 
signal.  This would likely result in an underestimation of differences in protein levels 
when signal is very high, and have implications for accurate reporting of differences in 
signal.  However, signal appeared to increase linearly with increasing amount of protein 
at both low and high ranges (Figure 1).  For one of the two proteins tested (SERCA1), 
there was a decrease in signal (compared to what was expected with a linear increase) 
when 20µl (corresponding to 20µg of protein) was loaded into a well.  Since this occurred 
in a sample that showed low signal (in addition to one that showed high signal), it is 
possible the drop off observed was due to some other confounding factor, and not due to 
the signal saturating at high values.  The drop off observed in the sample showing low 
signal occurred around 20,000,000 AUs—a value that was well within the linear range 
with the sample showing high signal.  Although the wells in the gels used were supposed 
to fit 20µl, it is likely that some of the sample was not contained within the well when 
20µl was loaded.  Attempting to fill the wells with 20µl of sample likely resulted in 
overflow, and less than 20µg of protein (20µl of sample) in the well.  14µg of protein 
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(corresponding to ~14µl of sample) was loaded per well for the western blots that 
investigated differences in target proteins.  Hence, the possibility of overflow in these 
cases was highly unlikely. 
Limitations Regarding Disease Controls 
It is possible that results for the SMA condition in the psoas only analyses would have 
been skewed, hence this group was excluded from analyses.  Two of the three SMA 
psoas samples were on the same membrane.  In a group with only n = 3, having two of 
the three samples on the same membrane could lead to protein expression for this group 
being over-estimated or under-estimated, if that particular membrane showed very high 
or very low signal.  Indeed, signal for SERCA1 on this particular membrane was well 
above the norm.  Hence, comparisons to the SMA group in the psoas only analyses were 
not made. 
In addition to possible limitations related to the lineup of SMA samples on the 
membrane, the disease control samples (SMA) used in this experiment were not age 
matched to ALS samples.   Healthy control samples that were age matched to the SMA 
samples were obtained as well as healthy control samples age matched to ALS.  In this 
study SMA was chosen as the disease CON since its etiology, also being a motor neuron-
specific neurodegenerative disease, was closest to that of ALS.  However, SMA and 
CON-SMA samples were from infants, since SMA types I and II have a pediatric 
lethality, while the average age of individuals from which the ALS samples came was 63 
years.  As such, it is most likely that differences observed between ALS or ALS age-
matched healthy controls and SMA or SMA age matched controls (CON-SMA) ware due 
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to difference in age, rather than disease (or control) conditions.  No significant 
differences in any target proteins were found between SMA and CON-SMA, further 
supporting the possibility that age affected protein expression.  As such, this discussion 
will focus on differences between ALS and healthy, age-matched controls only. 
Differences in Protein Levels Between ALS and Healthy Controls 
Levels of Akt and Grp78/BiP were significantly different between ALS and healthy 
controls.  In congruence with the results observed in ALS mice, Akt and Grp78/BiP 
levels were higher in ALS compared to CON.  Akt is a protein involved in protein 
synthesis, and is activated upon phosphorylation. Interestingly, Leger et al (2006) found 
no differences in Akt mRNA between ALS and controls, but a decrease in 
phosphorylated Akt (the active form)/ Akt ratio in ALS skeletal muscle.  Taken together 
with the results of the present experiment, it is possible there is a decreased ability to 
phosphorylate Akt in ALS.  Thus, more of the protein remains in the inactive form. 
The ER chaperone protein Grp78/BiP is up-regulated when an unfolded protein 
stress response is detected in the cell (77).  The present experiment shows that Grp78/BiP 
is up-regulated in ALS skeletal muscle, providing support for the presence of the UPR in 
ALS skeletal muscle.  Although other studies have investigated Grp78/BiP expression in 
spinal cord sections in ALS (147), the present study is the first to show alterations in 
Grp78/BiP in skeletal muscle. 
Calcium regulation is impaired in motor neurons of individuals with ALS (17) 
and in skeletal muscle of ALS mice (28).  Although not statistically significant, SERCA1 
levels in the present study in all muscles combined were ~40% lower in ALS compared 
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to healthy controls (Figure 6).   Impaired calcium homeostasis has a direct effect on 
mitochondrial function, can stimulate mitochondrial ROS production, and activate 
apoptotic pathways (15).  Mitochondrial dysfunction is well established in ALS (17, 48, 
86), and several authors have suggested mitochondrial pathogenesis is outside of the 
mitochondria itself (86, 141).  Although more research is necessary, results from the 
present study present the possibility that mitochondrial dysfunction could be caused (at 
least in part) by misregulated calcium homeostasis resulting from reduced calcium 
clearance proteins in the SR.  The present study extends previous research addressing 
alterations in calcium regulating proteins and ER stress proteins in motoneurons and 
spinal cord sections in individuals with ALS and in skeletal muscle of a mouse model of 
ALS to human skeletal muscle (Figure 14). 
 
Figure 14. ER stress, mitochondrial dysfunction, calcium misregulation and reactive oxygen 
species (ROS) are implicated in ALS pathology (132). 
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The ratio of the SR/ER calcium pumps SERCA2 (found in type I muscle fibers), 
to SERCA1  (found in type II muscle fibers) was significantly lower in human ALS 
skeletal muscle compared to control muscle.  Diaphragm muscles showed a particularly 
high SERCA2/SERCA1 ratio.  Because none of the control samples in this study were 
from diaphragm muscles, it cannot be determined if the high SERCA2/SERCA1 ratio in 
diaphragm is specific to ALS or occurs in control diaphragms as well.  If specific to ALS, 
a higher SERCA2/SERCA1 ratio could indicate a fiber type shift from type II to type I 
fibers.  More likely, this increased SERCA2/SERCA1 ratio in diaphragm muscles could 
be due to decreased levels of SERCA1 protein independent of a fiber type shift, since 
SERCA2 levels were not different between diaphragm and quadriceps muscles.  It is 
possible that diaphragm muscles are affected more than quadriceps muscles in ALS, 
which is logical considering death most often occurs due to respiratory failure.  
Grp78/BiP and CHOP levels were also significantly higher in diaphragm compared to 
quad muscles in ALS, perhaps indicative of increased ER stress. Future research that 
includes quadriceps and diaphragm control muscles is necessary to clarify if these 
differences are unique to ALS. 
Differences in Protein Levels in Different Muscles 
Having only psoas muscles for healthy controls and many different muscles for ALS 
cases presented both an opportunity to investigate differences in protein levels in 
different muscles in ALS and a limitation, because differences found in ALS could not be 
compared to control muscle.  Results of analyses involving psoas muscles only were 
similar to those of all muscles, indicating that psoas muscles in ALS are fairly 
representative of the “average” muscle.  However, vast differences were seen between 
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diaphragm and psoas muscles, indicating that these muscles could be particularly affected 
(or unaffected) in ALS.  These findings bring to light the possibility that different 
muscles are affected differently in ALS.  This information is useful in guiding future 
research—both in considerations for study designs and potential areas to investigate 
further. 
Protein levels were not affected by C9orf72 
Target protein levels were not significantly different between individuals that had a 
C9orf72 mutation and those that did not.  For many individuals genetic testing was not 
performed (or if so the results were not obtained), in which case these individuals were 
not included in C9orf72 analyses.  This resulted in fewer samples per group, reducing 
statistical power.  Regardless, protein expression in ALS cases that had or lacked this 
mutation tended to be similar, so it is unlikely that differences would occur even if more 
samples were analyzed.   
 Significant differences were observed between the group with the mutation and 
controls, as well as the group lacking the mutation and controls.  This, along with the lack 
of a difference in expression between the +/- C972orf groups, indicates that the 
mechanisms underlying skeletal muscle pathology investigated in the present experiment 
are not affected by a C9orf72 mutation.  Not surprisingly, Grp78/BiP levels were higher 
in +/- C9orf72 ALS cases compared to controls, as was also the case when considering all 
ALS samples compared to controls.  Interestingly, SERCA1 levels were significantly 
lower in +/- C9orf72 cases compared to controls, but not significantly different between 
all ALS and controls.  This is potentially due to different muscles being included in +/- 
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C9orf72 cases compared to all ALS cases.  There were no quadriceps or bicep muscles in 
the +/- C9orf72 cases, and these two muscles showed the highest levels of SERCA1 
protein when all ALS cases were considered.   The remainder of the target proteins 
showed similar trends to what was observed when all ALS samples were compared to 
controls. 
Protein Levels Were Not Significantly Different Between fALS and sALS 
Similar to the C9orf72 results, analyses of protein levels in fALS, sALS and controls 
showed similar trends to what was observed when all ALS samples were included.  No 
significant differences were found between fALS and sALS, but differences were 
observed for SERCA1 and Grp78/BiP in either of these ALS groups when compared to 
controls.  As was the case for the C9orf72 analyses, fALS and sALS cases did not contain 
any quadriceps or bicep muscles, resulting in lower SERCA1 levels compared to all ALS 
cases.  Considering the overlap between genes involved in sALS and fALS, it is not 
surprising that no significant differences between these two groups were observed. 
β-actin Was Significantly Different Between Limb and Bulbar Onset 
β-actin was the only target protein for which expression was significantly different 
between an ALS sub-group—in this case, limb and bulbar onset.  Levels of β-actin in 
limb onset were significantly higher than levels in bulbar onset and controls, while levels 
in bulbar onset were lower than that of controls.  This provides further evidence that β-
actin is not a reliable loading control in ALS muscle. 
 Not surprisingly, expression trends for bulbar/limb onset compared to controls 
tended to be similar to observed differences when considering all target proteins, with the 
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exception of CHOP.  CHOP showed similar expression between bulbar onset and 
controls, whereas CHOP expression tended to be higher in ALS than in controls. 
Study Limitations and Future Directions 
Clinical information on autopsy samples was incomplete.  For example, site of 
onset of symptoms and muscle from which the sample came is not known for all samples.  
As a result of this, the number of samples that were included in analyses comparing 
differences in proteins between such subgroups was limited, resulting in reduced power 
to detect differences.  In addition, the amount of time from death to when samples were 
taken differs between samples.  Although the manner in which this effects protein 
expression is unknown, it is possible this uncontrolled variable affected the results of the 
experiment.   
The nature in which samples were assigned to different membranes was not ideal 
for the exploratory analyses of various subgroups.  In this study, samples were 
randomized across 8 membranes.  Ideally, separate western blots would be run for each 
of the different sub analyses, and all membranes would contain an equal number of 
samples from each sub group that is being analyzed (e.g., for the site of onset analysis, a 
separate western blot would be run with only the samples to be used in this specific 
analysis, alternating groups across lanes [i.e., limb, bulbar, CON, limb, bulbar, CON], 
with an equal amount of samples from each group on the membrane).  Due to limited 
resources, conducting separate western blots for each of the different exploratory 
analyses was not feasible.  Hence, the number of samples in each subgroup was not 
completely balanced between the different membranes.  As was the case with the 
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analyses of psoas muscles in the SMA group, it is possible that other sub analyses could 
have been affected by distribution of samples across membranes.   The exploratory 
analyses conducted were useful to identify potential differences in protein levels in a cost 
effective manner.  The results of the present study can be used to guide follow-up 
experiments on alterations in skeletal muscle proteins in various subgroups of ALS.   
As mentioned previously, the lack of age-matched disease controls was also a 
limitation in this study.  Ideally, analyses would involve three age-matched groups: ALS, 
healthy control and diseased control. 
Future studies may consider investigating the effect of exercise on protein 
expression in ALS muscle. To this author’s knowledge, no previous studies have 
investigated changes in SERCA1, SERCA2, PDI, Grp78/BiP, CHOP, or Akt in ALS 
muscle in response to exercise training in individuals with ALS.   Akt activation is known 
to increase with exercise (38).  Perhaps an exercise intervention in ALS could “rescue” 
some of the decline in Akt activation that presumably occurs. The greatest effects on 
survival and motor function observed in ALS mice to date were seen with combined 
exercise training and IGF-I therapy (76).  However, it is not known if increases in IGF-I 
associated with exercise training (rather than due to a drug intervention) would also elicit 
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Chapter 5: Review of Literature 
 ALS is a complicated disease that is not completely understood.  A number of 
different pathophysiological mechanisms and ALS-linked genes have been identified and 
investigated.  The ALS phenotype is very heterogeneous, and often difficult to diagnose 
clinically.  Clinical features and diagnostic criteria, ALS genetics, pathophysiological 
mechanisms, and treatments will be reviewed. 
Disease Statistics 
ALS, commonly known as Lou Gehrig’s disease after the renowned New York 
Yankees first baseman who contracted the disease in 1939, is the most common fatal 
neurodegenerative disorder in adults, with approximately 4 cases of ALS per 100,000 
persons in the United States (103).  Significant deviations from this incidence rate have 
been found in several ethnic populations; American Indians and Alaska Natives show 
lower incidence (0.63 cases per 100,000 persons (64), while incidence in two towns in 
Japan’s Kii Peninsula was found to be significantly higher (33 and 20 persons per 
100,000 (7)). Incidence of ALS in the Chamorro population on the Marianas island of 
Guam was reported at one time to be 50-100 times greater than anywhere else in the 
world—400 per 100,000 individuals (9).  
Approximately 30,000 Americans have ALS at any given time and on average 15 
new cases are diagnosed daily.  The disease is 1.6 times more common in men vs. women 
and twice as common in Caucasians than in African Americans (103).  The average age 
at diagnosis is 59 (83), and the highest prevalence rates are seen between 70-79 years of 
age (103).  There are individuals with age at onset < 25 years old (termed Juvenile ALS).  
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In these cases, the disease tends to progress much more slowly than what is observed 
with adult onset (110). Average survival time from diagnosis is 19 months and from 
onset is 30 months, although much variability in these averages are seen (93).  Indeed, 
10% of ALS patients live longer than 10 years after diagnosis (110).  Factors associated 
with shorter survival include older age at symptom onset, severe cognitive impairment, 
shorter interval between symptom onset and diagnosis, poorer motor function at first visit 
and bulbar onset of symptoms (62, 63, 65).  
Diagnosing ALS 
Individuals with ALS show vast variability in symptoms in the early stages of the 
disease.  No biological diagnostic marker exists, and a progression of motor neuron 
degeneration must be observed to warrant an ALS diagnosis.   As a result, ALS 
diagnostic timelines are often long, and frequent misdiagnoses occur.  Median diagnostic 
time (defined as time from symptom onset to confirmed diagnosis) for individuals with 
ALS is approximately 11.5 months. On average patients see three physicians before an 
ALS diagnosis is given, and half receive an alternate diagnosis first.  Diagnostic timelines 
tend to be longer for individuals with sALS, limb onset, and those over the age of 60 
(134) (109).   
El Escorial criteria for diagnosing ALS.  ALS is marked by progressive 
degeneration of both UMNs ( motor neurons in the cerebral cortex and brainstem) and 
LMNs (motor neurons in the spinal cord) and progressive muscle weakness.  To warrant 
an ALS diagnosis, progressive UMN and LMN findings must be observed by 
examination and history (65).  El Escorial criteria have been widely utilized for 
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diagnosing ALS.  According to the El Escorial criteria, requirements for an ALS 
diagnosis include: evidence of LMN and UMN degeneration and progressive spread of 
symptoms, along with absence of evidence of other disease processes that could explain 
the degeneration (23).   
ALS may be diagnosed clinically without pathological confirmation, based on the 
presence of UMN and LMN signs.  In these cases, the terms Clinically Definite, 
Clinically Probable, or Clinically Possible ALS are used, each having specific criteria 
relating to the region affected and number of UMD and LMN signs that are present (23).  
See Table 3 for a summary of this criteria. 
Table 3.  El Escorial Criteria for the Clinical Diagnosis of ALS (from P. H. Gordon, 2013b). 
 
Clinicians may also specify numerous ALS and ALS-like syndromes.  When ALS 
is present in at least one other generation, it is recognized as Genetically- determined 
(familial/hereditary) ALS (fALS).  In these familial cases, if a pathogenic mutation has 
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been determined, the diagnosis may be upgraded to Clinically Definite Familial ALS- 
Laboratory- supported.  When no genetic link is established, the case is considered 
sporadic (sALS).  ALS-Plus Syndromes may also be recognized, if other neurological 
diseases develop in parallel with ALS.  Common ALS-Plus Syndromes include dementia 
and extra-pyramidal features.  When symptoms are caused by non-ALS pathology, the 
terminology ALS-Mimic syndrome can be used.  These syndromes include 
endocrineopathies, post-poliomyelitis, multifocal motor neuropathies, lead intoxication, 
and various infections (23).   
Electrophysiological, neuroimaging, and neuropathalogical studies.  When a 
clinical diagnosis of ALS is made, electrophysiological studies are typically performed to 
confirm LMN dysfunction in clinically affected areas or potentially detect LMN 
dysfunction in areas that were clinically uninvolved.  Conventional electromyographic 
(EMG) needle examinations can provide electrophysiological evidence of active and 
chronic denervation (both of which are requirements of an ALS diagnosis), which often 
appear clinically as fibrillations and fasciculations.  To support an ALS diagnosis, EMG 
signs must be observed in at least two of the following locations: bulbar/cranial motor 
neurons in the brainstem, anterior horn motor neurons in the cervical, thoracic, or lumbar 
spinal cord.  The presence of fasciculation potentials in EMG recordings is also 
characteristic of ALS and can assist in diagnoses.  Other techniques may be used to 
assess denervation, including single fiber or macro EMG, quantitative motor unit 
potential analyses, and motor unit number estimates.  Nerve conduction and 
neuroimaging studies are also administered, primarily to exclude other disorders that may 
mimic ALS (23).   
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Detecting UMN involvement in ALS early in progression is difficult.  Single-
voxel magnetic resonance spectroscopy (MRS), diffusion tensor imaging (DTI) and 
transcranial magnetic stimulation (TMS) may be used as objective tests for clinical UMN 
signs, but their sensitivity early on is questionable (78, 143).  Brain and spinal MRI are 
useful in excluding other diseases that affect UMNs, such as cervical spondylosis (23).  
Transcortical motor stimulation has recently been utilized in research settings, and does 
show cortical motor hyperexcitability in early stages of ALS.  This technique identified 
UMN signs that were not detected by conventional exam, resulting in earlier diagnosis 
for many individuals.  Although much more research and development is needed before 
this technique can be made available in clinical settings, researchers are hopeful it will 
allow for earlier diagnosis of ALS in the near future (56, 130).  
Muscle and/or biopsy studies may support or exclude a diagnosis of ALS; 
however, the only method of definitively proving an ALS diagnosis is by autopsy 
examination (23).   
Clinical Symptoms and Phenotypes 
Phenotypically, ALS is markedly heterogeneous—even when considering family 
members with the same genetic mutation.  The site of symptom onset may vary, UMNs 
and LMNs may be differentially affected, and vast differences in cognitive and 
behavioral effects may be present.  Indeed, some suggest ALS is not a distinct disease, 
but a syndrome that exhibits a continuum of UMN/ LMN involvement and cognitive 
impairment, and other neurodegenerative diseases may fall under the ALS syndrome 
umbrella.  Given the vast heterogeneity, ALS is often characterized by the site of 
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symptom onset, degree of involvement of UMNs and LMNs, and presence or absence of 
cognitive impairments. 
Limb versus bulbar onset.  ALS includes two main forms of onset: limb 
(sometimes referred to as spinal) and bulbar.  Of the two, limb onset is more common and 
is associated with longer survival (62, 64).   The first symptoms noticed are typically 
unilateral and focal weakness in a limb.  Individuals often have difficulty walking, 
frequently tripping or stumbling, develop a foot drop, or have difficulty writing or 
holding utensils due to loss of dexterity in the hand.   
In the case of bulbar onset, individuals typically begin to have difficulty speaking 
and swallowing.  Dysarthria and dysphagia often progress to anarthria and malnutrition 
due to difficulties eating.  Tongue atrophy and fasciculations are classic characteristics of 
bulbar onset ALS.   Median survival time from onset of symptoms is ~27 months in 
individuals with bulbar onset, but highly variable (134).  The prognosis for bulbar onset 
is worse than that for limb onset, in part because bulbar onset patients are prone to 
aspiration and malnutrition and potentially due to earlier respiratory dysfunction.   
Although ALS is more common in males than females, bulbar onset ALS has a female 
predominance, suggesting possible involvement of sex hormones in location of onset 
(24).   
A small percentage of ALS patients (~4%) are characterized by respiratory onset.  
Spinal and/or bulbar involvement is often mild or absent in these cases, and prognosis is 
very poor (1.4 years on average) (29).   
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Involvement of UMNs and LMNs.  Physicians consider muscle weakness, 
atrophy, hyporeflexia, cramps, and fasciculations signs of LMN involvement, while 
mood lability, hyperreflexia, muscle spasticity, and hypertonia are designated as UMN 
signs (65, 131).  “Typical” or “classical” ALS is marked by simultaneous UMN and 
LMN weakness. If the involvement of either the UMNs or LMNs is drastically skewed, 
special designations are given: UMN-dominant (UMN-D) or LMN-dominant (LMN-D) 
ALS.  Differentiating between these ALS subtypes and other neurodegenerative diseases 
with similar symptoms, such as Primary Lateral Sclerosis (PLS) and Progressive Muscle 
atrophy (PMA), is often challenging.   
A diagnosis of PLS is designated for individuals exhibiting only UMN 
involvement.  EMG is typically used to assess nerve dysfunction.  Many individuals 
initially presenting with only UMN involvement eventually develop LMN sign, so 
frequent re-evaluations of patients showing only UMN signs is recommended (59).  A  
“clinically pure” PLS diagnosis is associated with a lack of LMN involvement (indicated 
by negative EMG) four years after the onset of symptoms, since only ~23% of 
individuals who develop LMN involvement due so after 4 years from diagnosis (60).  
Individuals with PLS typically survive for decades. Even slight involvement of LMNs 
(EMG-positive findings) in individuals diagnosed with PLS is associated with a poorer 
prognosis, similar to that of individuals with classical ALS showing predominantly UMN 
signs (UMN-D ALS), suggesting possible misdiagnosis (59).   
UMN-D ALS is less common than LMN-D ALS, and is not as well characterized.  
Mean age at onset in UMN-D ALS (52 years) tends to be lower than in classic ALS (61.4 
years), and the disease tends to progress slower than what is observed in classic ALS 
	   55	  
(disease durations of 56 and 33 months, respectively) (119). 
On the other end of the spectrum, PMA is characterized by dysfunction of LMNs 
only.  In essence, PMA is equivalent to ALS without UMN involvement.  It is generally 
accepted that PMA evolves into ALS in some cases.   In a review of 91 charts of 
individuals diagnosed with PMA, 20 of the patients later developed UMN symptoms, 
typically within 2 years of the PMA diagnosis, which qualifies them as having LMN-D 
ALS (79). Additionally, among individuals with a PMA diagnosis that had MRS studies 
conducted, over half showed UMN abnormalities. Interestingly, the presence of UMN 
signs in these cases was not significantly related to survival time although prognosis for 
individuals with PMA tends to be better than ALS prognoses.  Risk factors for poor 
survival are congruent between the two diagnoses. Furthermore, mutations in the SOD1 
gene have also been identified in PMA patients (27).  Given the parallels between the two 
diseases, it has been suggested that PMA should be considered a form of ALS rather than 
a separate disease (79).   
In some individuals with ALS, lower motor neuron involvement is limited to 
upper limbs or lower limbs for at least 12 months, known as flail arm syndrome and flail 
leg syndrome, respectively.  In either case motor neuron degeneration spreads to all 
limbs, however, progression in these cases appears to be slightly slower than in classic 
ALS (81) (145). 
The ALS spectrum.  Multiple lines of evidence suggest that ALS, PLS, and PMA 
represent differing ends of a spectrum of the same disease (see Figure 15)(Su, 2014). 
However, differential diagnoses are helpful for researchers attempting to select 
homogenous participants for clinical trials (or at least as homogeneous as possible, given 
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the heterogeneity of ALS phenotypes) and for providing individuals with prognoses.   
Patients showing only LMN involvement (PMA) have a slightly better prognosis than 
individuals diagnosed with ALS (79), while those with only UMN involvement tend to 
have a much better prognosis (59).  Consistent with the spectrum, prognosis for 
individuals with UMN-D ALS falls between that of classic ALS and PLS ((29, 119).  
Figure 15.  The PMA-ALS-PLS spectrum.  The spectrum is based on involvement of UMNs and 
LMNs.  In PMA (far left), only LMNs are affected, while in PLS (far right) only UMNs are 
affected.  In ALS, both UMNs and LMNs are involved, however, the degree to which each is 
affected can vary (UMN-D ALS and LMN-D ALS).  (Adapted from Swinnen, 2014) 
Cognitive impairment in ALS.  The degree and nature of cognitive impairments 
associated with ALS varies between individuals.  Historically cognitive impairments with 
ALS were considered uncommon, but more recent research reveals this is not the case.  
An investigation of 131 French patients with ALS showed 40% had cognitive impairment 
and 10% had overt frontotemporal lobar degeneration (FTLD) (61).    These results were 
corroborated in a recent study in which one-third of participants with ALS showed 
diminished performance on a simple frontal task involving word generation.  In a subset 
of patients that consented to further neurological testing, nearly all of the individuals with 
diminished word generation met strict research criteria for FTLD and approximately 25% 
of the individuals that did not display diminished word generation met criteria for FTLD.  
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Many of these patients showed new onset personality changes, which is associated with 
frontotemporal dementia (FTD), a sub-classification of FTLD (94).   
ALS-FTLD is associated with shorter survival time and is more likely to occur in 
patients with bulbar onset compared to individuals with classic ALS (61, 108).  
Individuals with ALS-FTLD were two times more likely to be noncompliant with 
noninvasive positive-pressure ventilation (NPPV) and percutaneous endoscopic 
gastrostomy (PEG).  Noncompliance rates were 75% and 72%, respectively, compared to 
38% and 31%, respectively, in individuals with classic ALS (108).  It is unclear if shorter 
survival time for individuals with cognitive impairment is due to non-compliance or other 
underlying factors.    
 Interestingly, individuals with comorbid FTD were 3.5 times more likely to carry 
a genetic mutation than individuals that did not present with FTD (33).  These findings 
highlight a genetic link between ALS and FTD.  Similar to the PMA-ALS-PLS spectrum, 
researchers have also proposed an ALS-FTD spectrum, in which individuals are 
characterized by the degree of motor neuron and frontotemporal neuron involvement (see 
Figure 16) (131).  
Figure 16. The ALS-FTD spectrum.  The spectrum is based on the involvement of motor neurons 
and frontotemporal neurons.  Individuals with classic ALS (far left) do not show signs of 
cognitive abnormality (no involvement of frontotemporal neurons; strictly motor neuron 
involvement), while those with FTD (far right) show no motor abnormalities.  Moving from left 
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to right on the spectrum: individuals with ALS that show behavioral impairment (ALSbi) and 
cognitive impairment (ALSci) indicate some involvement of frontotemporal neurons.  Those with 
ALS-FTD meet criteria for both diagnosis, and thus exhibit involvement of both frontotemporal 
neurons and motor neurons.  Individuals with FTD-MND have some motor neuron involvement 
but do not meet criteria for an ALS diagnosis (Adapted from Swinnen, 2014). 
 
Treatments for ALS  
Therapeutic interventions.  There is currently no cure for ALS.  The only FDA-
approved drug for treating ALS is Riluzole, which increases lifespan by approximately 3 
months (104).  Over 100 compounds have been as potential therapeutic interventions for 
ALS (see Wu et al 2014 for a complete list of compounds).  Although many were 
effective in mice, translating the results to humans has not been successful (23).  
Examples of compounds that were successful in mice but failed in clinical trials include: 
creatine monohydrate (68), Vitamin E (67), COX2 inhibitors (37), and IGF-I (21, 87, 
127).  Questions have arisen on the ability of the common mouse model to accurately 
represent the pathophysiology underlying the majority of human ALS cases.  It appears 
the SOD1 pathophysiology (seen in the most common mouse model) is quite different 
from that of other ALS linked genes, offering a possible explanation for why 
interventions that were successful in this model failed in ALS clinical trials (95).  
Clinical trials involving the use of stem cell therapies are currently underway.  
Although stem cell research as a therapeutic intervention for ALS is in the early stages, it 
appears treatments that focus on increasing neural protection are promising, while those 
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involving motor neuron transplants are unlikely to be successful.  The length of time it 
typically takes for ALS to be diagnosed presents a barrier for stem cell interventions; 
often, neural degeneration is well advanced by the time the disease is diagnosed, at which 
point cells may be past the point of repair.  Hence, diagnosing ALS as early as possible 
will likely be imperative to the effectiveness of stem cell treatments (101).  
Exercise as a therapeutic intervention for ALS.  In healthy individuals, free 
radical production as a result of oxidative phosphorylation during exercise results in 
increased antioxidant enzymes and resistance to oxidative stress (112).  This led 
researchers to explore exercise as a possible intervention to reduce oxidative stress in 
ALS patients.  However, the relationship between exercise and ALS patient outcomes 
remains unclear.  Some studies suggest that high intensity endurance training hastens a 
decrease in motor performance and death in SOD1 mice (98).  As a result of these 
findings and studies associating competitive sport participation and ALS development, it 
is not uncommon for ALS patients to be advised to avoid physical activity, in hopes of 
preserving muscle strength and minimizing muscle damage (124).  However, research 
has also shown positive effects of moderate exercise in mouse models of ALS (4, 6)(80)  
as well as positive effects of moderate exercise on disability in ALS patients (8, 19, 47).  
Furthermore, it is possible outcomes are dependent on specific exercise type (42), 
intensity (76), and sex (98, 140).  
Although the precise relationship between exercise and ALS risk and disease 
progression remains unclear, several studies suggest that muscle exercise may be 
beneficial.  In an ALS patient case study, strength gains were seen in 14 of 18 muscle 
groups following 75 days of resistance training (19).  Short-term positive effects were 
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also seen in male ALS patients from a muscle exercise program.  Patients who 
participated in two 15 minute sessions of daily muscle training exercises designed to 
improve endurance, involving modest loads and significant changes in length, showed 
significantly less deterioration in muscle spasticity and global functioning as assessed by 
the ALS Functional Rating Scale (ALSFRS) (1) than patients who did not perform this 
type of exercise.  Although no significant differences were found between groups at 6 
months, there was a trend toward less deterioration in the treated group (47).  Significant 
differences have been observed at the 6 month timeframe between exercising and non-
exercising ALS patient groups on the ALSFRS and in patient quality of life assessed by 
the SF-36 (8), with individuals who participated in a resistance training program 
reporting less decline in global functioning and quality of life than those who did not. 
These individuals also showed less decline in leg strength than individuals who did not 
participate in resistance training.  However, no differences were seen in fatigue severity 
as assessed by the Fatigue Severity Scale (7) between groups  (3).   
Although few studies have been conducted on the efficacy of resistance training 
in ALS patients, there does appear to be some degree of short-term benefit for patient 
quality of life.  Muscle exercise may help to attenuate the declines in muscle strength and 
spasticity seen in ALS patients and increase patient quality of life.  To this author’s 
knowledge, no studies to date have investigated the effects of any other types of exercise 
in ALS patients aside from resistance exercise.  More research is needed to determine if 
other types of exercise may be beneficial for ALS patients. 
Evidence for exercise training efficacy in mouse models of ALS.  Research on 
the effects of exercise training in mouse models of ALS has yielded conflicting results.  
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Some studies report exercise training hastens onset of motor performance declines and 
decreases lifespan (98), others report beneficial effects of exercise on motor function (42, 
80), and still others report exercise has no effect on motor function and survival (91).  
Different exercise intensities (4) and types of exercise (5) have been shown to produce 
differential effects on outcome measures.  Differences in methods between studies may 
account for inconsistencies in results, as quantifications of exercise intensities, duration, 
and exercise type vary greatly. Furthermore, particular outcomes may also be dependent 
on gender (140).  
Altogether, the data suggest a potential protective effect of moderate exercise 
(corresponding to speeds around 13 m/min) in the form of running on motor 
performance, motor neuron survival and lifespan in ALS mice.  Moderate exercise 
appears to delay the onset of symptoms, at least in female mice (140), and decrease the 
rate of decline in motor performance after symptom onset (26).  Combined IGF-I therapy 
and exercise show synergistic effects in ALS mice; the combined treatment resulted in 
the greatest increase in lifespan observed of any study to date involving exercise with 
ALS mice (76).  It appears that intense running (corresponding to speeds around 22 
m/min) may hasten the onset of motor performance deficits and potentially decrease 
lifespan in ALS mice (98).  Given that ALS mice exhibit increased free radical 
production (5)(2) it is possible that high intensity exercise “tips the scale” so to speak, 
increasing oxidative stress to the point of cellular damage and death, while moderate 
exercise increases free radical production enough to increase antioxidant capacity, but not 
so much that cells are harmed.  Measures of oxidative stress in future studies would be 
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helpful in determining the exact role of oxidative stress in the results seen at different 
exercise intensities.  
Exercise in the form of swimming.  Different types of exercise elicit different 
cellular responses and adaptations (120).  In addition to exercise intensity, type of 
exercise appears to play a critical role in effecting motor function and life span in SOD1 
mice.  Specifically, when comparing male G93A*SOD1 mice trained in swimming, 
running, and sedentary mice, mice trained in swimming show delayed onset of symptoms 
(16 days in swimming vs. sedentary ALS mice; no significant difference in running vs. 
sedentary mice), less deterioration in motor function and strength, and increased life span 
(25 days in swimming vs. sedentary ALS mice) (42). 
Current care for individuals with ALS.  Participation in multidisciplinary care 
results in increased quality of life (89) and longer survival (133) in individuals with ALS.  
In these setting, individuals may interact with physicians, respiratory therapists, speech 
therapists, physical therapists and case coordinators or social workers, among other 
service providers.  Delivering services in a multidisciplinary fashion helps to provide 
continuity and consistency of care for patients, and reduce the burden of traveling to 
multiple locations for various appointments with different service providers.  (51) 
The majority of ALS patients die from respiratory failure, resulting from an 
inability to contract the diaphragm.  Respiratory support, such as noninvasive ventilators 
(NIV), improve sleep quality (70) and increase  survival (22) when used at least 4 hours 
per day.  All care for individuals with ALS is palliative.  In the later stages of the disease, 
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the primary goal is to avoid suffering.  Medications can be given for pain, anxiety, and to 
assist with sleep (65).  
Healthcare and Caregivers 
Healthcare costs for ALS patients are substantial and increase drastically as the disease 
progresses.  Annual costs are estimated at approximately $5,000 per year in the early 
stages of the disease and $80,000 per year in later stages of the disease.  Due to the 
severity and extremely fast progression of the disease, ALS patients are typically unable 
to work within a rather short timeframe of being diagnosed.  Although insurance 
companies may cover some costs, coverage is not consistent.  Sources of costs include 
medications to help manage symptoms and reduce pain, non-invasive ventilators and 
mechanical ventilators, and frequent emergency room and office visits.  During the later 
stages, patients typically need a fulltime caregiver, often resulting in lost wages of family 
members taking on the responsibility (105).  It is estimated that caregivers of individuals 
with ALS spend an average of 11 hours per day with the patient, even when paid 
assistance is also being received (84).  Interestingly, although nearly half of primary 
caregivers report feeling physically and/or psychologically unwell (84), rates of caregiver 
depression were shown to decline from earlier on in disease progression to patient death 
or near death (111). 
Potential Causes of ALS 
About 5-10% of ALS cases are genetically inherited (fALS), most often as an 
autosomal dominant trait.  The remaining 90-95% of cases are sporadic (sALS) and the 
cause is unknown, although sALS is thought to have both genetic and environmental 
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influences (64, 131). Genetic predispositions, exposure to toxins, and trauma may play a 
role in some cases of ALS.  Although the cause is unknown, military Gulf War veterans 
are approximately twice as likely to develop ALS (3). Some researchers suggest a 
relationship exists between sports participation and development of ALS, but the 
literature on this topic is conflicting. 
Genes linked to ALS.  At least 22 genes have been identified that are linked to 
ALS (see Figure 18) (35).  The most common genes associated with ALS, which account 
for just over half of fALS cases, are superoxide dismutase 1 (SOD1), transactive response 
DNA-binding protein of 43 kD (TARDP), fused in sarcolemma/ translated in liposarcoma 
(FUS/TLS) and c9orf72 (see Figure 17).  An additional 10-15% of fALS cases are 
accounted for by several other recently discovered genes, including OPTN, VCP, 
SQSTM1, PFN1, and UBQLN2 (115).  These ALS-linked genes serve numerous cellular 
functions, including RNA processing (TARDP and FUS/TLS), endosomal trafficking and 
cell signaling (C9ORF72 and OPTN), oxidative stress (SOD1), and ubiquitin/protein 
degradation (UBQLN2, VCP, and SQSTM1).  Additionally, mutations in many of the 
same genes have been discovered in at least 9% of sALS cases (115); very recent 
research utilizing more advanced genome mapping techniques suggest this number may 
actually be as high as 27% (25). 
	   65	  
 
Figure 17.  ALS linked genes in fALS (top) and sALS (bottom).  At least 22 genes have been 
linked to ALS, the most common of which are shown here.  Interestingly, similar mutations are 
found in both fALS and sALS. (115). 
SOD1.  In the early 1990s, researchers identified a close genetic linkage between 
fALS and the SOD1 gene.  SOD1 is an antioxidant enzyme that combats the free radical 
superoxide anion (118).  Currently, 15% of fALS cases are due to mutations in SOD1 and 
1% of sALS patients also carry similar SOD1 mutations (30).  Mean age at onset is 
approximately three years earlier for individuals with a SOD1 mutation (M= 46.9, SD= 
12.5) compared to those lacking a mutation (M= 50.5, SD= 11.5) (36), and bulbar onset 
in SOD1 cases is extremely rare (131).  Although over 160 mutations in the gene have 
been identified (65), a genetic link has only been observed in a portion of these (4). There 
is considerable phenotypic variability associated with different SOD1 mutations.  The 
most common mutation is an alanine for valine substitution at codon 4 (A4V), which is 
associated with a severe form of ALS that progresses rapidly and is correlated with 
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shorter survival.  Conversely, G37R, G41D, and G93C mutations predict longer survival 
(36). 
The discovery that ~15% of fALS patients carry a point mutation on the SOD1 
gene (118) led to the development of a transgenic mouse model of ALS in which the 
mutant human SOD1 gene is overexpressed.  The G93A*SOD1 mouse model is the most 
common ALS mouse model, in which there is a point mutation in the 93rd codon, where a 
glycine is replaced with an alanine (69). These mice show motor neuron degeneration 
similar to that seen in humans with ALS, expressing symptoms such as hind limb 
weakness and atrophy beginning around 3 months of age, progressing to complete 
paralysis typically around 5 months of age.  The G93A*SOD1 mouse model most closely 
resembles the severe cases of human ALS with rapid progression and poor prognosis 
(40).  Although the development of this mouse model has provided a platform for 
examination of the underlying disease mechanisms, the model’s use for testing potential 
pharmacological treatment approaches for humans is questionable (95). 
Formation of protein aggregates/inclusions in the cytoplasm of degenerating 
motor neurons is characteristic of neurodegenerative diseases.  In ALS, ubiquinated 
inclusions containing TDP-43 (most often) and/or FUS (in some cases) proteins are a 
hallmark of the disease (6).  Mutations in the SOD1 gene are toxic, gain-of-function 
mutations that increase cellular oxidative stress and result in ubiquinated TDP-43 
negative SOD1 protein aggregates in affected tissues.  The aggregates are found in the 
highest abundance in the brain stem and spinal cord anterior horn, and have shown 
resistance to a protease digest that successfully degrades wild type SOD1 (129).  The 
mechanism underlying SOD1 toxicity in motor neurons is not completely understood, but 
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there is evidence to suggest that non-neuronal cells may contribute to the damage of 
motor neurons.  Indeed, lowering mutant SOD1 expression in microglia of ALS mice 
significantly slowed disease progression (20).  Less neuronal death and prolonged 
survival was also seen in mice that expressed wild type microglia compared to those that 
expressed microglia with a SOD1 mutation (13), suggesting microglia play a causative 
role in neurodegeneration in SOD1 ALS cases.  
Because of the distinct difference in presence/absence of TDP-43 in these protein 
aggregates, it has been suggested that SOD1 ALS is caused by a different mechanism 
than all other forms, and may require selective treatment.   This may also explain (at least 
in part) the lack of efficacy of therapeutic interventions in humans that were successful in 
the SOD1 mouse model (97, 115).  
TARDP.  The discovery that TDP-43 protein is a primary constituent of 
cytoplasmic neuronal inclusions in ALS (6) led to the linkage of TARDP (the gene that 
encodes the TDP-43 protein) gene mutations to fALS (128).   As the name suggests, 
normal TAR DNA-binding Protein-43 is a DNA/RNA binding protein that regulates 
transcription, alternative splicing and microRNA biogenesis, and is typically localized to 
the nucleus.  Conversely, pathological TDP-43 is hyperphosphorylated, ubiquinated, and 
cleaved at the N-terminus.  Localization to the cytoplasm occurs, presumably due to 
cleavage of the nuclear localization signal at the N-terminus.  A number of specific 
mutations in TARDP have been identified that are linked to fALS, accounting for 
approximately 4% of fALS cases (33).  TDP-43 mutations have also been identified in a 
small percentage of sALS cases, however, the presence of TDP-43 pathology in ALS is 
much greater than the mutational frequency of the gene.  Moreover, TDP-43 positive 
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ubiquinated inclusions are also hallmark of FTLD, which shows frequent co-occurrence 
with ALS (107). 
FUS/TLS.  Not long after the discovery of TARDP involvement in ALS, an 
additional protein with similar function to TDP-43 was liked to ALS.   Mutations in 
FUS/TLS, a nuclear RNA and DNA binding protein that is involved in transcription and 
RNA splicing, were discovered in approximately 5% of fALS cases and are often linked 
to Juvenile ALS (115).  Similar to TDP-43, FUS protein aggregates were a primary 
constituent of cytoplasmic inclusions in individuals with a mutated FUS gene.   The 
functional homology between FUS and TARDP suggests that the two may function in the 
same pathway, sharing a common pathophysiological mechanism that leads to 
neurodegeneration (85, 139). 
C9orf72.  Of the common genes associated with fALS, C9orf72 is the most 
recently discovered (44, 116) and the most common, accounting for ~40% of fALS cases 
(99).  Furthermore, it accounts for 7% of sALS cases, making it the only gene whose 
alteration has been linked to a significant number of sALS cases (compared to all other 
genes which account for less than this amount combined).  It was also found to account 
for ~24% of familial FTD, providing genetic evidence for the overlap between the two 
diseases (99).  Contrary to individuals with SOD1 mutations, bulbar onset is very 
frequent in cases of C9orf72 (131).  Shorter survival time is also seen in individuals with 
C9orf72 mutations compared to the average ALS survival time (33). 
Specifically, massive hexanucleotide repeat expansions in the non-coding region 
of C9orf72 are observed in C9orf72 linked ALS and FTD, making C9orf72 unique from 
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other ALS-associated genes.   Penetrance for individuals with the expansion is ~50% by 
age 58, and nearly 100% by 80 years of age (99).  A number of modifying genes have 
been identified that are associated with the heterogeneity observed in individuals with 
C9orf72 repeats, including UBAP1, metallothionein, UNC13A, and ELP3.  These genes 
code for proteins with varying functions, including protein sorting, antioxidant defense, 
neurotransmitter release, and RNA synthesis, and were shown to modify disease 
characteristics such as age at onset and survival after onset (136).   
Genes involved in degradation and endosomal trafficking.  Other genes have 
recently been identified that account for a small portion of fALS cases.  Several are 
involved in ubiquitin and protein degradation, while others function in endosomal 
trafficking and cell signaling.  Valosin-contining protein (VCP) mutations, known to 
cause inclusion body myopathy with FTD, are present in  ~1-2% of fALS cases (74, 82).   
The presence of VCP gene mutations in both ALS and FTD provide further evidence for 
a genetic linkage between the two diseases.  TANK-Band Kinase 1 (TBK1) was very 
recently implicated as an ALS gene; this protein plays an important role in autophagy and 
inflammation, and phosphorylates both Sequestome 1 (SQSTM1) and Optineurin 
(OPTN), both of which have previously been implicated in ALS (53, 102).  SQSTM1 and 
OPTN serve as cargo receptors for ubiquinated proteins’ engulfment into 
autophagosomes, and OPTN specifically functions in the autophagy of damaged 
mitochondria (146).  Interestingly, OPTN is present in both SOD1 and TDP-43 positive 
inclusions, suggesting it may be involved in broader ALS pathogenesis (102).  SigR1 
mutations, also recently linked to ALS (1), appear to lead to impaired autophagic 
degradation as well. SigR1 loss of function also causes ER pathology, mitochondrial 
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abnormalities, and destabilization of lipid rafts (142).  VCP, TBK1, SQSTM1, OPTN and 
SigR1 all appear to play critical roles in the removal of pathological protein aggregates 
via degradation and autophagy, highlighting the involvement of this malfunction in the 
pathophysiology of ALS (34).   
Other ALS linked genes.  In 2012, Wu et al discovered that mutations in the 
Profilin 1 (PFN1) gene account for ~1-2% of fALS (148).  The authors suggest mutant 
PFN1 protein alters dynamics of growing actin filaments, inhibiting axon outgrowth.  
They also provide evidence for the possibility of PFN1 inducing aggregation of TDP-43 
(148).  Additionally, mutations in Ubiquilin 2 (UBQLN2) have been identified as the 
cause of an X-linked juvenile and adult-onset form of fALS.  UBQLN2 function is 
similar to that of other ALS-linked genes (VCP and SQSTM1), as it is involved in protein 
degradation, specifically of ubiquinated proteins (45).  See Su et al 2014 for a complete 
list of ALS- associated genes. 
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Figure 18.  ALS- linked genes (35). 
fALS versus sALS.  The discovery that many genes responsible for fALS are also 
found in some sALS cases is important when considering the fALS verses sALS 
classification system.  Some have proposed the possibility of an underlying genetic 
component in all of ALS (88) that is influenced by environmental factors, making certain 
individuals more or less susceptible to the disease (115).  Recently, researchers have 
begun to investigate an oligogenic model of ALS, in which mutations in two or more 
genes leads to development of the disease (88).  It has been suggested that a genetic 
variant leads to susceptibility to ALS and a second locus effects specifics of the disease 
such age of onset, progression, and/or phenotype (137).  Indeed, inhibition of EPHA4 
signaling increases survival in mouse and rat models of ALS, and expression of EPHA4 
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in humans is inversely correlated with disease onset and survival (138).  Moreover, in 
SOD1 ALS mice, concomitant mutations in the homologue of human H63D HFE, a 
protein involved in oxidative stress and alterations in iron homeostasis, resulted in 
decreased survival and acceleration of disease progression (106).  A comprehensive study 
that investigated 17 ALS-linked genes in individuals with ALS found that 3.8% of 
subjects had variants in >1 gene, and disease onset for these individuals was 10 years 
earlier, on average.  Additionally, these researchers found that 27.8% of sALS individuals 
carried a known ALS-linked mutation—a much larger percentage that what has been 
previously found (25). Although significant progress has been made since the discovery 
of SOD1 ~25 years ago, much research is still needed to fully understand the 
involvement of genetic factors in ALS. 
A complicated relationship between pathogenesis and phenotype.  ALS is 
characterized by upper and lower motor neuron death and progressive muscle weakness, 
but vast phenotypic differences are seen in limb versus bulbar onset, the degree of 
associated cognitive deficits, and differential involvement of UMNs and LMNs.  The 
distinctiveness of these phenotypes would seem to suggest different causal mechanisms, 
however, there are no neuropathic or genetic factors that can definitively distinguish 
between them (114).   Conversely, different gene mutations associated with fALS result 
in highly similar, if not identical, phenotypes and sALS and fALS are phenotypically 
indistinguishable from one another.  Although specific mutations may tend to show 
certain phenotypes (e.g. bulbar onset is very frequent with c9orf72 mutations and rare in 
cases with SOD1 mutations), vast variability is still observed.  Any of the known genetic 
mutations may be associated with a number of observed clinical phenotypes (i.e. bulbar 
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onset, limb onset, age at onset, rate of progression, predominantly UMN/LMN, classical 
ALS, etc.).  This suggests the involvement of other modifying factors, such as 
environmental factors and/or other genes that may serve a protective function or 
exacerbate the disease.  Many different gene mutations yield the same phenotype, 
suggesting there must be numerous different underlying mechanisms with similar 
pathophysiological pathways that have the potential to cause ALS.  Additionally, the 
ability of a specific gene mutation to result in a number of different clinical phenotypes 
highlights the complexity of the underlying disease mechanism and the possibility of 
extensive gene-gene or gene-environment interactions that can significantly affect 
phenotype. 
Sports participation and development of ALS.  Early epidemiological studies 
showed a relationship between previous participation in competitive sports and ALS 
incidence.  36% of ALS patients reported earning varsity letters in high school, while 
only 12% of diseased controls and 20% of healthy controls reported this achievement 
(54).  These findings were supported by a more recent study, in which incidence of motor 
neuron disease was 1.7 times higher in patients who were varsity athletes vs. those who 
were not (121).  Increased risk for development of ALS was reported among Italian 
soccer players, in particular midfielders and individuals with careers lasting longer than 5 
years (31). It has been proposed that the increased risk observed in this population may 
be due to increased trauma or abuse of both legal and illegal drugs (32). However, 
subsequent studies failed to show an association between competitive sports or sports 
related traumas and development of ALS (135).  Performance enhancing dietary 
supplements, specifically branched chain amino acids, have recently received further 
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attention as a possible contributing factor to increased ALS incidence in athletes (14, 
100).  At this time, the relationship between competitive sports and ALS development 
remains unclear.  
ALS Pathophysiology is Complex 
Although the pathophysiology of ALS is not completely understood, several 
theories have been proposed, including oxidative stress, impaired calcium signaling, 
mitochondrial dysfunction, protein misfolding and glutamate toxicity (20, 132).  Two 
organelles receiving growing interest in ALS pathophysiology research are the 
sarco/endoplasmic reticulum (SR/ER) and mitochondria. 
Sarco/endoplasmic reticulum stress is linked to ALS pathology.  The ER, a 
multifunctional organelle, has two major functions in the cell: it is a site of Ca2+ storage 
and release, and is involved in protein synthesis and facilitation of proper protein folding 
(16).  Alterations in one of the primary functions of the ER can greatly affect the other.  
Very sensitive to changes in homeostasis, during times of stress many ER stress-signaling 
pathways are activated resulting in alterations in protein expression.  Ongoing protein 
synthesis is turned off, proteins that enhance cell survival may be up- regulated and/or 
apoptotic pathways may be initiated.  Under conditions of ER stress, misfolded proteins 
can accumulate in the ER, inducing an unfolded protein response (UPR) (77).  A primary 
cause of protein misfolding and activation of the UPR is deficient Ca2+ stores in the ER 
lumen.  Conversely, the accumulation of misfolded proteins can cause misregulated Ca2+ 
release or uptake in the ER (16).  Impaired Ca2+ regulation and misfolded protein 
accumulation have both been implicated in ALS pathology. 
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Calcium regulation is impaired in ALS.  G93A*SOD1 transgenic mice have 
shown increased intracellular Ca2+ in single muscle fibers, likely due to decreased Ca2+ 
clearance proteins (28).  After skeletal muscle contraction, the sarco/endoplasmic 
reticulum Calcium-ATPases (SERCA1 and SERCA2) function as pumps, moving Ca2+ 
from the cytosol back into the ER lumen for storage.  Protein levels of SERCA1, found in 
type II muscle fibers, as well as SERCA2, located in type I fibers, were drastically 
reduced in G93A*SOD1 transgenic mice gastrocnemius muscle.  In addition, the Ca2+ 
handling protein PV, involved in relaxation in type II fibers, was also reduced. Mutations 
in SigR1, known to cause a juvenile form of ALS, have been shown to affect Ca2+ 
homeostasis by destabilization of lipid rafts.  Loss of SigR1 function has also been linked 
to deformities in the ER ultrastructure (142).  Furthermore, mutant SOD1 expression in 
astrocytes was shown to result in elevated intra-mitochondrial Ca2+ levels in motor 
neurons and decreased mitochondrial membrane potential (17).   
Reactive oxygen species are linked to motor neuron death and Ca2+ handling.  
An additional known cause of ER stress and the UPR, also linked to ALS, is the 
accumulation of ROS. Oxidative stress is caused by an imbalance between the production 
of ROS or free radicals and the cell’s ability to detoxify these intermediates or repair 
damage caused by ROS.  The SOD1 mutation found in the G93A*SOD1 mouse model is 
a gain of function mutation, increasing SOD1 activity, resulting in increased production 
of reactive oxygen species (ROS) (18).  G93A*SOD1 mice show increased free radical 
production that results in protein damage (5).  High levels of oxidative stress leading to 
cell damage have also been implicated in motor neuron death in individuals with ALS 
(11, 12).  The hydroxyl radical, production of which is increased in G93A*SOD1 mice, 
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has been shown to inhibit SERCA protein function (149).  Given the role of SERCA1 in 
Ca2+ regulation, it is not surprising that ROS production is also linked to altered Ca2+ 
regulation (16).    
SR-mitochondrial coupling, ROS, and Ca2+ signaling.  Mitochondria are 
plentiful in skeletal muscle, providing ATP for contraction and playing a key role in Ca2+ 
homeostasis (48).  Often found in very close proximity to the SR, the two are “coupled,” 
with various signaling mechanisms between them, and alterations in one organelle often 
resulting in changes in the other.   Formation of mitochondrial networks within muscle 
fibers (i.e., mitochondrial fusion) has been observed, and is essential to proper 
bioenergetics and excitation-contraction coupling (52).  Ca2+ released from the SR upon 
activation of the ryanodine receptor—such as during muscle contraction— accumulates 
in intermyofibrillar mitochondria, activating enzymes in the mitochondrial matrix that 
enhance ATP production (excitation-oxidative metabolism coupling) (75, 123). 
Movement of Ca2+ from the ER/SR lumen into the mitochondria can also stimulate ROS 
production in the mitochondria and activate apoptotic pathways.  Conversely, 
mitochondrial ROS can leak into the ER and regulate ER Ca2+ release channels, creating 
bidirectional information transmission between the ER and the mitochondria that is Ca2+ 
dependent (16).   
Evidence for mitochondrial alterations in ALS is plentiful (17, 48, 86, 141, 144), 
although it appears that mitochondrial dysfunction may be a result of pathophysiology 
upstream or outside of the mitochondria itself.  Expression of multiple mitochondrial 
DNA (mtDNA) genes is reduced in ALS spinal cord tissue (e.g. COX3, ND2, ND4).  
This decrease is thought to be the result of alterations in upstream PGC-1α signaling, 
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rather than a primary pathogenic event (86).   Reduced expression of mtDNA coding for 
COX and NADH:coQ oxidoreductase has also been observed in ALS skeletal muscle 
(141, 144).  In this case, it was proposed that oxygen radicals, specifically SOD, were to 
blame for the mitochondrial alterations (141). 
The superoxide anion radical, which is the SOD substrate, is the major reactive 
oxygen species produced in mitochondria (125).  Mutant SOD1 has been shown to induce 
leakage of the outer mitochondrial membrane and expansion of the intermembrane space, 
resulting in mitochondrial degeneration and vacuolation (73).  When mutant G93A SOD1 
neuroblastoma, non-neuronal Madin-Darby Canine Kidney (MDCK), and NSC-34 
motoneuronal-like cell lines were investigated, mitochondrial alterations were seen only 
in motoneuronal-like cell lines, suggesting selective vulnerability of motoneuronal 
mitochondria in particular to mutant G93A SOD1 (113). Muscle mitochondria 
uncoupling results in destruction of the neuromuscular junction and mild degeneration of 
motor neurons, suggesting that motor neuron death may be caused by pathology outside 
of the motor neuron (49). 
Although the precise mechanisms underlying ALS pathophysiology are not clear, 
there is compelling evidence to suggest that dysfunction in skeletal muscle Ca2+ 
regulation and ROS production in the ER/SR and mitochondria play a role.  Further 
research is needed to understand the precise mechanisms behind ALS pathophysiology. 
Preferential motor unit loss in ALS.  The cause of motor neuron death in ALS 
is not well understood.  Research in G93A*SOD1 transgenic mice indicates that motor 
unit death occurs selectively in units of larger muscle fibers and prior to motor neuron 
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loss.   Decreases in force production in muscles composed of primarily type II fibers, but 
not in muscles composed primarily of type I fibers, were seen at 80 days of age, prior to 
declines in the number of motor neurons and onset of overt symptoms.  At 40 and 80 
days of age, ALS mice had a 22% and 48% (respectively) reduction in motor units in 
muscles composed primarily of type II fibers, but no significant reduction in motor units 
in muscles composed primarily of type I fibers, in comparison to controls (71).  
Furthermore, at 60 days of age, muscle from the tibialis anterior (primarily type II fibers) 
of G93A*SOD1 mice contained 40% less innervated fibers, 60% less motor units, and a 
44% higher innervations ratio when compared to wild type mice, however, force 
production per motor unit was lower in ALS mice.  The same mice showed 65% less IIB 
fibers, 28% less IID/X fibers and about twice as many IIA fibers than the wild type mice.  
This indicates selective denervation of fast-twitch fatigable and fatigue intermediate 
fibers and reinnervation of these muscle cells by slower fatigue resistant type IIA motor 
neurons (72).  Decreased competence for synaptic sprouting-- in type IIB fibers, 
specifically-- is likely to play a role in the selective denervation seen in ALS.  There is a 
strong inverse relationship between susceptibility to synapse loss and the ability to 
produce synaptic sprouting in ALS mice (55). 
Alterations in Human Skeletal Muscle Protein Expression in ALS 
 Previous studies have shown mRNAs and proteins involved in muscle 
hypertrophy and atrophy are altered in ALS skeletal muscle.  mRNA and protein 
expression of Atrogin-1, a protein involved in muscle atrophy, are significantly elevated 
in ALS mice and human skeletal muscle (90).  Akt, which has anabolic effects and is 
thought to be an upstream regulator of Atrogin-1 (58), is also altered in ALS.  Skeletal 
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muscle biopsies from individuals with ALS showed a 68% decrease in phosphorylated 
Akt (the active form) to Akt ratio when compared to healthy control muscle.  However, 
downstream Akt target proteins p70s6k and GSK-3β were not different between ALS and 
control muscle (90).  The IGF-I family proteins, also upstream regulators of Akt, are 
altered in ALS as well.  IGF-I family proteins include IGF-I, a trophic factor that is 
implicated in muscle and nerve anabolism, and IGF- Binding Proteins which may 
potentiate or inhibit IGF-I activity.  IGF-I and IGF-Binding Proteins that have the ability 
to potentiate IGF-I showed decreased expression in ALS human skeletal muscle, and the 
IGF-I receptor β subunit showed increased expression.  
Recent work discovered a correlation between Akt, as well as Factor XIIIB, and 
overall survival in individuals with ALS.  In a screening of 143 cell-function related 
proteins and phosphoproteins, significant differences between human ALS and healthy 
control skeletal muscle were found in seventeen proteins.  Individuals that showed high 
expression of Akt or Factor XIIIB had a better prognosis than individuals with low 
expression. In addition, expression of four proteins (p-GSK-3α/βSer21/9, p-RBSer780, p-
PKCαSer657 and SYK) was significantly correlated with ALS-Functional Rating Scale 
(Revised) scores <40, with lower scores indicating lower level of function.  Increased 
expression of the protein SK3 was related to greater muscle atrophy (150).   
The SR/ER transmembrane protein stromal interaction molecule 1 (STIM1) is 
also altered in ALS skeletal muscle (66).  STIM1 functions as a Ca2+ sensor on the SR/ 
ER membrane, activating store-operated Ca2+ entry (SOCE) channels when Ca2+ stores in 
the ER lumen are depleted.  Mutations that decrease STIM1 affinity for Ca2+ induce a 
permanent SOCE resulting in Ca2+ misregulation (92).  STIM1 is an important signaling 
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molecule in the initiation of myoblast differentiation that subsequently forms contractile 
myotubes (41).    Accumulation of STIM1 protein was found in partially and completely 
atrophied ALS muscle fibers, but was not present in healthy fibers.  Given that autophagy 
is regulated by Ca2+ homeostasis, it is possible that STIM1 plays a part in autophagy 
regulation in skeletal muscle (66).     
Summary 
 Although there is still much to understand about ALS pathophysiology, significant gains in 
understanding the underlying disease mechanisms and ALS genetics have been made in the past 
20 years.  Although many different genes with varying functions and various molecular pathways 
may be involved, the relationship between these pathways is beginning to come to light.  With 
this deeper understanding comes the potential for development of new treatments for this 
devastating disease for which there is no cure. 
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Appendices 
Appendix A 
SERCA1 expression was significantly lower in G93A SOD1 mice compared to controls 
(A) and also tended to be lower in individuals with the SOD1 mutation compared to other 
ALS subtypes and diseased controls (B).  Grp78/BiP was significantly higher in ALS 
mice compared to controls, and also tended to be higher in individuals with sALS and a 
C9orf72 mutation compared to SOD1 mutation and diseased controls.  
 
 
Figure A1.  Alterations in skeletal muscle proteins in ALS mice and human autopsy samples.  
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Appendix B 
Data in Figure A2 shows differences in Akt protein level between diseased control and 
different sub-groups of ALS.  This figure also demonstrates the approach in blinded 
analysis of protein levels (panels A and B) followed by un-blinded data analysis to 
examine trends across groups.  Protein level of Akt tends to be higher in SOD1 and sALS 






















Figure A2. Akt western blot results.  Akt western blot results (A) and membrane total protein 
stain (B) showing equal loading across lanes.  Akt signal for each lane is displayed (C), then 
researcher is un-blinded to sample identity for analyses (D). 
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Appendix C 
Chemiluminescent western blot results showing Akt antibody binding (A) and Alexa 
image (B) showing protein marker of known molecular weights were overlaid (C), 
allowing for identification of target protein bands by molecular weight.  Panel B also 
shows map of protein marker (provided by Bio-Rad) used to identify molecular weights 
of bands on the marker. 
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Appendix D 
An image was taken of all proteins on the SDS-PAGE gel immediately after 
electrophoresis (visualized via Bio-Rad Stain Free gels; panel A).  Stain free gels were 
imaged after proteins were transferred to PVDF membrane under the turbo transfer 
setting (proteins visible are those that remained on the gel after transfer and were not 
successfully transferred to PVDF membrane; panel B).  Total protein on the PVDF 
membrane was visualized with Bio-Rad stain free technique after probing for target 
protein (C).  Stain free images showed weak total protein signal.  A second PVDF 
membrane was inserted behind the target PVDF membrane to determine if proteins over-
transferred (through the first membrane; panel D).   
 
Figure A4. Results of condition optimization experiments for optimal western blotting transfer 
times.    
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Appendix E 
 
Western blot chemiluminescent images of target bands with 7.5 % gels (A) tended to be 
diffuse and difficult to accurately quantify, hence, 10% (B) and 12% (C) gels were used.   
 
Figure A5.  Western blot target protein chemiluminescent images with 7.5% (A), 10% (B), and 
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Appendix F 
 
Stain-free images were taken of total protein on the gel (A) and PVDF membrane (B). 
Total protein images on PVDF membranes obtained via stain-free technology were too 
faint and had too much background to accurately quantify.  Total protein images obtained 
with Memcode PVDF Stain (E) showed clear, prominent bands.  Chemiluminescent 
images of GAPDH (C) and β-actin (D) on the same membrane showed much variability 
across lanes.   Chemiluminescent image of ACTA1 (F) also showed much variability.  
Total protein stain obtained via Memcode PVDF Stain produced the most reliable results, 
and was selected as the loading control.   
 
 
Figure A6.  Western blot results of loading control experiments.  Note: A-D are from the same 
gel/ membrane and E-F are from the same membrane.  
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Appendix G 
IRE1α chemiluminescent images showed high background and non-specific binding.  
Target band was unidentifyable, therefore, this protein was excluded from the study.   
Figure A7.  Western blot results showing inability to identify target band corresponding to IRE1α 
(130 kDa).  Panel A is an overlay of Alexa image (showing protein ladder) and chemiluminescent 
image.  Panel B is chemiluminescent image only.  Double-headed arrow shows where target band 
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Appendix H 
 
 SPSS data from comparisons of protein levels between disease groups (ALS, CON, 
SMA, CON-SMA) for each target protein are shown.  One-way between subjects 
ANOVA with LSD post hoc analyses were used. 
Table A1.  Descriptive statistics for disease groups. 
  N Mean 
Std. 
Deviation Std. Error 
95% Confidence Interval for 
Mean 





1 ALS 38 47,470,872 64,191,641 10,413,259 26,371,605 68,570,139 1.20E+06 2.24E+08 
healthy 
control 13 79,243,663 73,560,886 20,402,119 34,791,264 123,696,061 1.29E+07 2.26E+08 
SMA 7 132,463,641 213,618,593 80,740,239 -65,100,606 330,027,889 450840.00 5.89E+08 
SMA 
control 
3 105,349,353 151,680,232 87,572,623 -271,445,231 482,143,937 1.33E+06 2.79E+08 
Total 61 66,841,874 98,999,750 12,675,619 41,486,861 92,196,887 450840.00 5.89E+08 
A
kt
 ALS 38 94,261,937 62,180,996 10,087,090 73,823,552 114,700,322 1.00E+07 2.35E+08 
healthy 
control 13 43,353,982 47,917,747 13,289,992 14,397,577 72,310,386 2.26E+06 1.71E+08 
SMA 7 117,595,063 36,943,467 13,963,318 83,428,054 151,762,071 7.84E+07 1.82E+08 
SMA 
control 3 97,537,068 25,463,201 14,701,186 34,282,971 160,791,166 8.02E+07 1.27E+08 





 ALS 38 50,856,808 63,639,054 10,323,618 29,939,171 71,774,444 1.35E+06 2.18E+08 
healthy 
control 13 28,556,806 42,686,415 11,839,081 2,761,664 54,351,949 1.53E+06 1.63E+08 
SMA 7 111,434,993 64,084,267 24,221,576 52,166,931 170,703,056 1.28E+07 2.05E+08 
SMA 
control 3 125,095,703 75,905,545 43,824,087 -63,464,124 313,655,529 5.61E+07 2.06E+08 
Total 61 56,707,037 65,125,046 8,338,408 40,027,738 73,386,335 1.35E+06 2.18E+08 
B
ip
 ALS 39 51,634,409 41,020,106 6,568,474 38,337,228 64,931,589 5.13E+06 1.74E+08 
healthy 
control 
13 14,483,527 19,883,948 5,514,815 2,467,778 26,499,277 1.26E+06 6.37E+07 
SMA 5 51,997,328 56,827,614 25,414,082 -18,563,475 122,558,130 5.36E+06 1.49E+08 
SMA 
control 
3 57,134,183 50,535,448 29,176,655 -68,402,830 182,671,196 170232.00 9.66E+07 
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Total 




P ALS 38 95,146,570 62,225,605 10,094,326 74,693,523 115,599,618 1.79E+07 2.67E+08 
healthy 
control 
12 74,113,151 47,347,042 13,667,914 44,030,275 104,196,026 2.20E+07 1.72E+08 
SMA 6 41,525,999 41,799,636 17,064,630 -2,340,029 85,392,027 893404.00 9.91E+07 
SMA 
control 
3 13,152,370 17,349,400 10,016,681 -29,945,930 56,250,670 645021.00 3.30E+07 
Total 59 81,246,450 59,970,048 7,807,435 65,618,171 96,874,730 645021.00 2.67E+08 
PD
I ALS 39 30,764,036 18,891,170 3,025,008 24,640,227 36,887,845 2.73E+06 1.01E+08 
healthy 
control 13 34,479,876 25,647,774 7,113,413 18,981,081 49,978,671 2.43E+06 8.67E+07 
SMA 7 29,638,620 31,777,751 12,010,861 249,102 59,028,138 3.06E+06 9.10E+07 
SMA 
control 3 19,733,108 21,232,211 12,258,423 -33,010,628 72,476,843 403410.00 4.25E+07 




 ALS 38 104,466,528 63,880,313 10,362,755 83,469,591 125,463,464 1.26E+07 3.03E+08 
healthy 
control 
13 161,107,268 133,779,109 37,103,649 80,265,361 241,949,175 3.90E+07 5.43E+08 
SMA 7 93,078,427 51,220,138 19,359,392 45,707,701 140,449,154 6.48E+06 1.75E+08 
SMA 
control 3 128,035,716 54,791,964 31,634,155 -8,075,068 264,146,501 6.62E+07 1.71E+08 
Total 61 116,389,814 83,974,379 10,751,817 94,882,978 137,896,651 6.48E+06 5.43E+08 
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Square F Sig. 
SERCA1 Between Groups 5.E+16 3 2.E+16 1.798 .158 
Within Groups 5.E+17 57 9.E+15     
Total 6.E+17 60       
Akt Between Groups 3.E+16 3 1.E+16 3.547 .020 
Within Groups 2.E+17 57 3.E+15     
Total 2.E+17 60       
BActin Between Groups 5.E+16 3 2.E+16 4.259 .009 
Within Groups 2.E+17 57 4.E+15     
Total 3.E+17 60       
Bip Between Groups 1.E+16 3 5.E+15 3.108 .034 
Within Groups 9.E+16 56 2.E+15     
Total 1.E+17 59       
CHOP Between Groups 3.E+16 3 1.E+16 3.240 .029 
Within Groups 2.E+17 55 3.E+15     
Total 2.E+17 58       
PDI Between Groups 6.E+14 3 2.E+14 .376 .771 
Within Groups 3.E+16 58 5.E+14     
Total 3.E+16 61       
Serca2 Between Groups 4.E+16 3 1.E+16 1.746 .168 
Within Groups 4.E+17 57 7.E+15     
Total 4.E+17 60       
 
  
	   91	  




(I-J) Std. Error Sig. 









1 ALS healthy control -31772791 31192836 .313 -94235368 30689786 
SMA -84992769* 39929943 .038 -164951101 -5034438 
SMA control -57878480 58220074 .324 -174462168 58705206 
healthy 
control 
ALS 31772790 31192836 .313 -30689786 94235368 
SMA -53219978 45512171 .247 -144356529 37916572 
SMA control -26105690 62181463 .676 -150621923 98410542 
SMA ALS 84992769* 39929943 .038 5034438 164951101 
healthy control 53219978 45512171 .247 -37916572 144356529 
SMA control 27114288 66992102 .687 -107035082 161263658 
SMA 
control 
ALS 57878480 58220074 .324 -58705206 174462168 
healthy control 26105690 62181463 .676 -98410542 150621923 
SMA -27114288 66992102 .687 -161263658 107035082 
A
kt
 ALS healthy control 50907955* 18060899 .007 14741628 87074283 
SMA -23333125 23119753 .317 -69629633 22963382 
SMA control -3275131 33709884 .923 -70778010 64227748 
healthy 
control 
ALS -50907955* 18060899 .007 -87074283 -14741628 
SMA -74241080* 26351908 .007 -127009866 -21472296 
SMA control -54183086 36003560 .138 -126278972 17912799 
SMA ALS 23333125 23119753 .317 -22963382 69629633 
healthy control 74241080* 26351908 .007 21472296 127009866 
SMA control 20057994 38788958 .607 -57615554 97731543 
SMA 
control 
ALS 3275131 33709884 .923 -64227748 70778010 
healthy control 54183086 36003560 .138 -17912799 126278972 
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 ALS healthy control 22300001 19403828 .255 -16555493 61155496 
SMA -60578185* 24838836 .018 -110317096 -10839275 
SMA control -74238894* 36216402 .045 -146760988 -1716801 
healthy 
control 
ALS -22300001 19403828 .255 -61155496 16555493 
SMA -82878187* 28311319 .005 -139570625 -26185749 
SMA control -96538896* 38680625 .015 -173995512 -19082281 
SMA ALS 60578185* 24838836 .018 10839275 110317096 
healthy control 82878187* 28311319 .005 26185749 139570625 
SMA control -13660709 41673133 .744 -97109718 69788300 
SMA 
control 
ALS 74238894* 36216402 .045 1716801 146760988 
healthy control 96538896* 38680625 .015 19082281 173995512 
SMA 13660709 41673133 .744 -69788300 97109718 
B
ip
 ALS healthy control 37150881* 12601987 .005 11906068 62395694 
SMA -362918 18691767 .985 -37807027 37081190 
SMA control -5499774 23576158 .816 -52728495 41728945 
healthy 
control 
ALS -37150881* 12601987 .005 -62395694 -11906068 
SMA -37513800 20707177 .075 -78995261 3967660 
SMA control -42650655 25203973 .096 -93140282 7838970 
SMA ALS 362918 18691767 .985 -37081190 37807027 
healthy control 37513800 20707177 .075 -3967660 78995261 
SMA control -5136855 28736951 .859 -62703886 52430175 
SMA 
control 
ALS 5499774 23576158 .816 -41728945 52728495 
healthy control 42650656 25203973 .096 -7838970 93140282 




P ALS healthy control 21033419 18798763 .268 -16640144 58706983 
SMA 53620570* 24939378 .036 3640941 103600200 
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SMA control 81994199* 34046008 .019 13764475 150223925 
healthy 
control 
ALS -21033419 18798763 .268 -58706983 16640144 
SMA 32587151 28385510 .256 -24298682 89472984 
SMA control 60960780 36645536 .102 -12478514 134400075 
SMA ALS -53620570* 24939378 .036 -103600200 -3640941 
healthy control -32587151 28385510 .256 -89472984 24298682 
SMA control 28373629 40143173 .483 -52075087 108822345 
SMA 
control 
ALS -81994199* 34046008 .019 -150223925 -13764475 
healthy control -60960780 36645536 .102 -134400075 12478514 
SMA 




 ALS healthy control -56640739* 26492091 .037 -109690238 -3591242 
SMA 11388101 33912521 .738 -56520550 79296752 
SMA control -23569188 49446338 .635 -122583772 75445396 
healthy 
control 
ALS 56640739* 26492091 .037 3591242 109690238 
SMA 68028841 38653510 .084 -9373477 145431159 
SMA control 33071552 52810748 .534 -72680147 138823250 
SMA ALS -11388101 33912521 .738 -79296752 56520550 
healthy control -68028841 38653510 .084 -145431159 9373477 
SMA control -34957289 56896426 .541 -148890416 78975838 
SMA 
control 
ALS 23569188 49446338 .635 -75445396 122583772 
healthy control -33071552 52810748 .534 -138823250 72680147 
SMA 34957289 56896426 .541 -78975838 148890416 
 
*. The mean difference is significant at the 0.05 level. 
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Appendix I 
The ratio of SERCA2/SERCA1 protein was significantly higher in ALS compared to 
CON.  SPSS analyses showed Levene’s test for equality of variances was significant 
(Table A5), so t-test results for equal variances not assumed were used. 
Table A4. Descriptive statistics for ratio of SERCA2/SERCA1 protein levels for ALS and 
CON. 
ALSCON N Mean Std. Deviation Std. Error Mean 
SERCA21ratio ALS 38 13.8702 21.46194 3.48159 
CON 
13 3.8850 2.78616 .77274 
 
 






Variances t-test for Equality of Means 


























assumed     2.800 40.433 .008 9.98525 3.56631 2.77986 17.19063 
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Appendix J 
SPSS t-tests revealed significant differences in Grp78/BiP, CHOP, SERCA2/SERCA1 
ratio, and SERCA1 between quadriceps and diaphragm muscles in ALS. 
 
Table A6.  Descriptive statistics for target protein levels in quad and diaphragm muscles 
in ALS. 
muscleanalysis N Mean Std. Deviation Std. Error Mean 
Bip quad 7 28779310.71 22110883.62 8357128.48 
diaphragm 3 79825420.33 45631721.94 26345486.95 
CHOP quad 7 50441546.00 23977617.02 9062687.38 
diaphragm 
3 103860866.33 31070804.76 17938737.49 
SERCA21ratio quad 7 1.48 1.43 0.54 
diaphragm 
3 12.55 1.27 0.73 
SERCA1 quad 7 95500456.57 75348323.22 28478989.28 
diaphragm 3 9185196.00 3360297.73 1940068.80 
Akt quad 7 134928642.71 61396441.33 23205673.59 
diaphragm 3 98735343.00 62603872.21 36144362.47 
BActin quad 7 61938114.43 56308980.96 21282794.31 
diaphragm 
3 23280364.00 20264916.87 11699955.21 
PDI quad 
7 30869133.14 14988937.97 5665286.04 
diaphragm 3 54513776.83 40197769.51 23208193.04 
Serca2 quad 
7 96000399.00 63151731.69 23869110.99 
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Table A7.  T-test results for differences in target protein levels between quad and 





of Variances t-test for Equality of Means 








95% Confidence Interval 


























































assumed .111 .748 .850 8 .420 36193300 42577400 -61990360 134376960 

















































	   98	  
Appendix K 
SPSS t-test results for differences in target protein levels between ALS and CON in psoas 
muscles are shown.  Grp78/BiP and CHOP protein levels were significantly higher in 
psoas muscles of ALS compared to CON.  Levene’s test for equality of variances was 
significant for Grp78/BiP (Table A7), so t-test results for equal variances not assumed 
were used. 
 
Table A8. Descriptive statistics for mean target protein levels in psoas muscles of ALS 
and CON. 
psoas N Mean Std. Deviation Std. Error Mean 
SERCA21ratio ALS 6 19 29 12 
CON 13 4 3 1 
SERCA1 ALS 6 53039110 85337051 34838705 
CON 13 79243663 73560886 20402119 
Akt ALS 6 47472699 34089327 13916910 
CON 13 43353982 47917747 13289992 
BActin ALS 6 53525322 74877065 30568434 
CON 13 28556806 42686415 11839081 
Bip ALS 6 76927621 57326843 23403586 
CON 13 14483527 19883948 5514815 
CHOP ALS 6 135170418 63426144 25893615 
CON 12 74113151 47347042 13667914 
PDI ALS 6 23850033 17153310 7002809 
CON 13 34479876 25647774 7113413 
Serca2 ALS 6 112754960 70222851 28668359 
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Table A9. T-test results comparing means of target protein levels in psoas muscles of 
ALS and CON. 
  
Levene's Test for 
Equality of 
Variances t-test for Equality of Means 




















assumed 16.259 .001 1.893 17 .076 15 8 -2 31 
not 








.026 .875 -.688 17 .501 -26204553 38107410 -106604160 54195055 
not 






.447 .513 .188 17 .853 4118717 21864642 -42011646 50249080 
not 








3.038 .099 .934 17 .363 24968516 26739206 -31446276 81383308 
not 






14.263 .002 3.585 17 .002 62444094 17419272 25692643 99195544 
not 







.646 .433 2.308 16 .035 61057268 26449700 4986408 117128127 
not 





1.169 .295 -.918 17 .372 -10629843 11583936 -35069812 13810125 
not 







.534 .475 -.826 17 .421 -48352308 58571162 -171926659 75222043 
not 
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Appendix L 
SPSS results for ANOVA in target protein levels between +C9orf72 cases, -C9orf72 
cases and CON. 
Table A10. Descriptive statistics for mean target protein levels in +/- C9orf72 cases and 
CON. 
  N Mean 
Std. 
Deviation Std. Error 











1 yes 7 13175395 11620125 4391994 2428572 23922218 5.77E+06 3.89E+07 
no 13 27433424 46187598 12810135 -477463 55344310 1.96E+06 1.68E+08 
con 13 79243663 73560886 20402119 34791264 123696061 1.29E+07 2.26E+08 
Total 33 44819087 60644577 10556866 23315456 66322719 1.96E+06 2.26E+08 
A
kt
 yes 7 76668092 56324671 21288725 24576459 128759724 1.81E+07 1.92E+08 
no 13 67681704 45380562 12586303 40258505 95104903 1.00E+07 1.67E+08 
con 13 43353982 47917747 13289992 14397577 72310386 2.26E+06 1.71E+08 





 yes 7 16438855 16750467 6331081 947256 31930453 4.56E+06 5.35E+07 
no 13 41510771 52600260 14588687 9724753 73296790 1.94E+06 1.94E+08 
con 13 28556806 42686415 11839081 2761664 54351949 1.53E+06 1.63E+08 
Total 33 31089409 43210312 7521950 15767698 46411119 1.53E+06 1.94E+08 
B
ip
 yes 7 52020565 37976519 14353775 16898143 87142988 1.22E+07 1.32E+08 
no 13 54622042 44734804 12407202 27589071 81655014 1.60E+07 1.74E+08 
con 13 14483527 19883948 5514815 2467778 26499277 1.26E+06 6.37E+07 




P yes 7 92878565 40354943 15252735 55556468 130200663 3.13E+07 1.38E+08 
no 13 99309800 57676742 15996650 64456094 134163507 2.12E+07 2.15E+08 
con 12 74113151 47347042 13667914 44030275 104196026 2.20E+07 1.72E+08 
Total 32 88454224 50317239 8894915 70312925 106595523 2.12E+07 2.15E+08 
PD
I yes 7 44499675 27587386 10427052 18985598 70013752 2.48E+07 1.01E+08 
no 13 26641546 15309307 4246038 17390225 35892868 2.73E+06 4.90E+07 
con 13 34479876 25647774 7113413 18981081 49978671 2.43E+06 8.67E+07 




 yes 7 106400652 37321589 14106235 71883940 140917365 4.55E+07 1.71E+08 
no 13 76713981 50421017 13984274 46244865 107183096 1.37E+07 1.78E+08 
con 13 161107268 133779109 37103649 80265361 241949175 3.90E+07 5.43E+08 
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Table A11. ANOVA results for differences in mean target protein levels between 
+C9orf72 cases, - C9orf72 cases, and CON. 
  
Sum of 
Squares df Mean Square F Sig. 
SERCA1 Between 
Groups 2.63E+16 2 1.32E+16 4.326 .022 
Within 
Groups 9.13E+16 30 3.04E+15     
Total 1.18E+17 32       
Akt Between 
Groups 6.31E+15 2 3.16E+15 1.328 .280 
Within 
Groups 7.13E+16 30 2.38E+15     
Total 7.76E+16 32       
BActin Between 
Groups 3.00E+15 2 1.50E+15 .792 .462 
Within 
Groups 5.68E+16 30 1.89E+15     
Total 5.97E+16 32       
Bip Between 
Groups 1.22E+16 2 6.08E+15 4.873 .015 
Within 
Groups 3.74E+16 30 1.25E+15     
Total 4.96E+16 32       
CHOP Between 
Groups 4.14E+15 2 2.07E+15 .807 .456 
Within 
Groups 7.43E+16 29 2.56E+15     
Total 7.85E+16 31       
PDI Between 
Groups 1.47E+15 2 7.35E+14 1.445 .252 
Within 
Groups 1.53E+16 30 5.09E+14     
Total 1.67E+16 32       
Serca2 Between 
Groups 4.72E+16 2 2.36E+16 2.789 .077 
Within 
Groups 2.54E+17 30 8.45E+15     
Total 3.01E+17 32       
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Table A12. LSD post hoc analyses for differences in mean target protein levels between 
+C9orf72 cases, - C9orf72 cases, and CON. 
Dependent Variable Mean Difference (I-J) Std. Error Sig. 
95% Confidence Interval 
Lower Bound Upper Bound 
SERCA1 yes no -14258029 25868666 .586 -67088892 38572834 
control -66068267* 25868666 .016 -118899131 -13237405 
no yes 14258029 25868666 .586 -38572834 67088892 
control -51810239* 21643278 .023 -96011710 -7608768 
control yes 66068267* 25868666 .016 13237405 118899131 
no 51810239* 21643278 .023 7608768 96011710 
Akt yes no 8986387 22854995 .697 -37689738 55662514 
control 33314110 22854995 .155 -13362016 79990236 
no yes -8986388 22854995 .697 -55662514 37689738 
control 24327722 19121860 .213 -14724327 63379771 
control yes -33314110 22854995 .155 -79990236 13362016 
no -24327722 19121860 .213 -63379771 14724327 
BActin yes no -25071917 20390057 .228 -66713968 16570134 
control -12117952 20390057 .557 -53760003 29524099 
no yes 25071917 20390057 .228 -16570134 66713968 
control 12953965 17059545 .454 -21886274 47794205 
control yes 12117952 20390057 .557 -29524099 53760003 
no -12953965 17059545 .454 -47794205 21886274 
Bip yes no -2601477 16555420 .876 -36412156 31209202 
control 37537037* 16555420 .031 3726359 71347716 
no yes 2601477 16555420 .876 -31209202 36412156 
control 40138514* 13851258 .007 11850472 68426558 
control yes -37537037* 16555420 .031 -71347716 -3726359 
no -40138514* 13851258 .007 -68426558 -11850472 
CHOP yes no -6431235 23737476 .788 -54979825 42117355 
control 18765415 24081160 .442 -30486087 68016917 
no yes 6431235 23737476 .788 -42117355 54979825 
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control 25196650 20269729 .224 -16259602 66652901 
control yes -18765415 24081160 .442 -68016917 30486087 
no -25196650 20269729 .224 -66652901 16259602 
PDI yes no 17858129 10577667 .102 -3744350 39460608 
control 10019799 10577667 .351 -11582679 31622278 
no yes -17858129 10577667 .102 -39460608 3744350 
control -7838330 8849911 .383 -25912260 10235601 
control yes -10019799 10577667 .351 -31622278 11582679 
no 7838329 8849911 .383 -10235601 25912260 
Serca2 yes no 29686672 43105370 .496 -58346238 117719582 
control -54706615 43105370 .214 -142739525 33326295 
no yes -29686672 43105370 .496 -117719582 58346238 
control -84393287* 36064540 .026 -158046904 -10739670 
control yes 54706615 43105370 .214 -33326295 142739525 
no 84393287* 36064540 .026 10739670 158046904 
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Appendix M 
SPSS results for ANOVA in target protein levels between sALS cases, fALS cases and 
CON. 
Table A13. Descriptive statistics for mean target protein levels in sALS, fALS, and CON. 
  N Mean Std. Deviation Std. Error 
SERCA1 sALS 17 26360052 40920870 9924769 
fALS 3 6556413 5035731 2907381 
control 13 79243663 73560886 20402119 
Total 33 45392659 60559079 10541983 
Akt sALS 17 65043431 43881703 10642876 
fALS 3 94845698 84536338 48807078 
control 13 43353982 47917747 13289992 
Total 33 59208400 50097513 8720858 
BActin sALS 17 34318033 47573193 11538194 
fALS 3 27372913 22640666 13071595 
control 13 28556806 42686415 11839081 
Total 33 31417084 43084432 7500037 
Bip sALS 18 63994984 46540662 10969739 
fALS 3 41340191 18219872 10519248 
control 13 14483527 19883948 5514815 
Total 34 43065180 42903958 7357968 
CHOP sALS 17 109095750 55088439 13360909 
fALS 3 68893182 37304727 21537894 
control 12 74113151 47347042 13667914 
Total 32 92208284 52794913 9332910 
PDI sALS 18 31406260 24550817 5786683 
fALS 3 33385712 7960616 4596064 
control 13 34479876 25647774 7113413 
Total 34 32756124 23574307 4042960 
Serca2 sALS 17 103500456 70587718 17120036 
fALS 3 92011072 27432181 15837977 
control 13 161107268 133779109 37103649 
Total 33 125149559 100632345 17517843 
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Table A14. ANOVA results for differences in mean target protein levels between sALS, 
fALS, and CON. 
  Sum of Squares df Mean Square F Sig. 
SERCA1 Between 
Groups 25579420271194600 2 12789710135597300 4.181 .025 
Within Groups 91777446485642500 30 3059248216188080     
Total 117356866756837000 32       
Akt Between 
Groups 7656573567603200 2 3828286783801600 1.581 .222 
Within Groups 72655771874718500 30 2421859062490620     
Total 80312345442321700 32       
BActin Between 
Groups 298484982459270 2 149242491229635 .076 .927 
Within Groups 59102098679829800 30 1970069955994330     
Total 59400583662289100 32       
Bip Between 
Groups 18513788160520200 2 9256894080260090 6.795 .004 
Within Groups 42230948945970600 31 1362288675676470     
Total 60744737106490800 33       
CHOP Between 
Groups 10408158700322200 2 5204079350161100 1.986 .156 
Within Groups 75998229189721600 29 2620628592749020     
Total 86406387890043800 31       
PDI Between 
Groups 72614711938039 2 36307355969020 .062 .940 
Within Groups 18267066923224800 31 589260223329833     
Total 18339681635162900 33       
Serca2 Between 
Groups 28070538708476800 2 14035269354238400 1.423 .257 
Within Groups 295989266315132000 30 9866308877171070     
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Table A15. LSD post hoc analyses for differences in mean target protein levels between 
sALS, fALS, and CON. 
Dependent Variable Mean Difference (I-J) Std. Error Sig. 
95% Confidence Interval 
Lower Bound Upper Bound 
SERCA1 sALS fALS 19803639.01961 34636761 .572 -50934063.0690 90541341.1083 
control -52883610.91629* 20378483 .014 -94502025.1428 -11265196.6897 
fALS sALS -19803639.01961 34636761 .572 -90541341.1083 50934063.0690 
control -72687249.93590* 35427055 .049 -145038947.5696 -335552.3022 
control sALS 52883610.91629* 20378483 .014 11265196.6897 94502025.1428 
fALS 72687249.93590* 35427055 .049 335552.3022 145038947.5696 
Akt sALS fALS -29802267.39216 30817992 .341 -92741004.3096 33136469.5253 
control 21689449.17195 18131717 .241 -15340456.3322 58719354.6761 
fALS sALS 29802267.39216 30817992 .341 -33136469.5253 92741004.3096 
control 51491716.56410 31521155 .113 -12883069.8432 115866502.9714 
control sALS -21689449.17195 18131717 .241 -58719354.6761 15340456.3322 
fALS -51491716.56410 31521155 .113 -115866502.9714 12883069.8432 
BActin sALS fALS 6945119.82353 27795260 .804 -49820373.1667 63710612.8138 
control 5761226.59276 16353297 .727 -27636660.6906 39159113.8762 
fALS sALS -6945119.82353 27795260 .804 -63710612.8138 49820373.1667 
control -1183893.23077 28429454 .967 -59244583.1259 56876796.6643 
control sALS -5761226.59276 16353297 .727 -39159113.8762 27636660.6906 
fALS 1183893.23077 28429454 .967 -56876796.6643 59244583.1259 
Bip sALS fALS 22654792.16667 23016927 .333 -24288539.9847 69598124.3180 
control 49511456.11538* 13434066 .001 22112496.9955 76910415.2353 
fALS sALS -22654792.16667 23016927 .333 -69598124.3180 24288539.9847 
control 26856663.94872 23640805 .265 -21359075.7655 75072403.6630 
control sALS -49511456.11538* 13434066 .001 -76910415.2353 -22112496.9955 
fALS -26856663.94872 23640805 .265 -75072403.6630 21359075.7655 
CHOP sALS fALS 40202567.79412 32057721 .220 -25362833.8256 105767969.4138 
control 34982599.21078 19301304 .080 -4493000.0242 74458198.4458 
fALS sALS -40202567.79412 32057721 .220 -105767969.4138 25362833.8256 
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control -5219968.58333 33044343 .876 -72803237.6493 62363300.4827 
control sALS -34982599.21078 19301304 .080 -74458198.4458 4493000.0242 
fALS 5219968.58333 33044343 .876 -62363300.4827 72803237.6493 
PDI sALS fALS -1979451.58333 15137924 .897 -32853451.8383 28894548.6717 
control -3073616.16026 8835405 .730 -21093544.2754 14946311.9549 
fALS sALS 1979451.58333 15137924 .897 -28894548.6717 32853451.8383 
control -1094164.57692 15548241 .944 -32805010.2287 30616681.0749 
control sALS 3073616.16026 8835405 .730 -14946311.9549 21093544.2754 
fALS 1094164.57692 15548241 .944 -30616681.0749 32805010.2287 
Serca2 sALS fALS 11489384.29412 62202417 .855 -115544899.5715 138523668.1597 
control -57606811.55204 36596693 .126 -132347229.8974 17133606.7933 
fALS sALS -11489384.29412 62202417 .855 -138523668.1597 115544899.5715 
control -69096195.84615 63621667 .286 -199028973.1909 60836581.4985 
control sALS 57606811.55204 36596693 .126 -17133606.7933 132347229.8974 
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Appendix N 
SPSS results for ANOVA in target protein levels between bulbar onset, limb onset, and 
CON. 
Table A16. Descriptive statistics for mean target protein levels in bulbar onset, limb 
onset, and CON. 
  N Mean Std. Deviation Std. Error 
SERCA1 bulbar 12 32174944 46207930 13339080 
limb 25 47760815 62942364 12588473 
control 13 79243663 73560886 20402119 
Total 50 52205747 63618041 8996950 
Akt bulbar 12 101777107 52314906 15102012 
limb 25 93481494 66853987 13370797 
control 13 43353982 47917747 13289992 
Total 50 82439288 62649148 8859927 
BActin bulbar 12 14112736 17299646 4993978 
limb 25 62736136 66491068 13298214 
control 13 28556806 42686415 11839081 
Total 50 42179894 56005269 7920341 
Bip bulbar 13 58747807 47405522 13147926 
limb 25 47534620 38619318 7723864 
control 13 14483527 19883948 5514815 
Total 51 41968095 40438060 5662461 
CHOP bulbar 12 72024888 46700688 13481327 
limb 25 100250676 61152316 12230463 
control 12 74113151 47347042 13667914 
Total 49 86937211 55428899 7918414 
PDI bulbar 13 32045029 14152833 3925290 
limb 25 30344643 21499895 4299979 
control 13 34479876 25647774 7113413 
Total 51 31832154 20754887 2906265 
Serca2 bulbar 12 120610186 74609170 21537812 
limb 25 93862280 57271206 11454241 
control 13 161107268 133779109 37103649 
Total 50 117765474 89615462 12673540 
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Table A17. ANOVA results for differences in mean target protein levels between bulbar 
onset, limb onset, and CON. 
  Sum of Squares df Mean Square F Sig. 
SERCA1 Between Groups 14812367812374600 2 7406183906187300 1.897 .161 
Within Groups 183503136339966000 47 3904322049786500     
Total 198315504152340000 49       
Akt Between Groups 27395268049953200 2 13697634024976600 3.904 .027 
Within Groups 164925602053484000 47 3509055362840090     
Total 192320870103438000 49       
BActin Between Groups 22429812438888700 2 11214906219444300 4.016 .025 
Within Groups 131263107833596000 47 2792832081565870     
Total 153692920272485000 49       
Bip Between Groups 14255137485863600 2 7127568742931820 5.068 .010 
Within Groups 67506699219585400 48 1406389567074700     
Total 81761836705449100 50       
CHOP Between Groups 9073215189496310 2 4536607594748160 1.508 .232 
Within Groups 138400200365677000 46 3008700007949490     
Total 147473415555173000 48       
PDI Between Groups 147041975090847 2 73520987545424 .165 .848 
Within Groups 21391223941285500 48 445650498776782     
Total 21538265916376400 50       
Serca2 Between Groups 38801820250424800 2 19400910125212400 2.571 .087 
Within Groups 354713797616209000 47 7547102076940620     
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Table A18. LSD post hoc analyses for differences in mean target protein levels between 
bulbar onset, limb onset, and CON. 
Dependent Variable Mean Difference (I-J) Std. Error Sig. 
95% Confidence Interval 
Lower Bound Upper Bound 
SERCA1 bulbar limb -15585871.11667 21943861 .481 -59731226.1073 28559483.8740 
control -47068718.68590 25013849 .066 -97390091.8979 3252654.5261 
limb bulbar 15585871.11667 21943861 .481 -28559483.8740 59731226.1073 
control -31482847.56923 21365986 .147 -74465666.7319 11499971.5935 
control bulbar 47068718.68590 25013849 .066 -3252654.5261 97390091.8979 
limb 31482847.56923 21365986 .147 -11499971.5935 74465666.7319 
Akt bulbar limb 8295612.84333 20803449 .692 -33555528.5507 50146754.2373 
control 58423125.31410* 23713891 .017 10716930.4975 106129320.1307 
limb bulbar -8295612.84333 20803449 .692 -50146754.2373 33555528.5507 
control 50127512.47077* 20255605 .017 9378490.4577 90876534.4839 
control bulbar -58423125.31410* 23713891 .017 -106129320.1307 -10716930.4975 
limb -50127512.47077* 20255605 .017 -90876534.4839 -9378490.4577 
BActin bulbar limb -48623400.24000* 18559345 .012 -85959986.6599 -11286813.8201 
control -14444070.23077 21155832 .498 -57004115.3384 28115974.8769 
limb bulbar 48623400.24000* 18559345 .012 11286813.8201 85959986.6599 
control 34179330.00923 18070598 .065 -2174024.5527 70532684.5712 
control bulbar 14444070.23077 21155832 .498 -28115974.8769 57004115.3384 
limb -34179330.00923 18070598 .065 -70532684.5712 2174024.5527 
Bip bulbar limb 11213187.37538 12823393 .386 -14569971.3213 36996346.0721 
control 44264279.73077* 14709440 .004 14688968.3612 73839591.1003 
limb bulbar -11213187.37538 12823393 .386 -36996346.0721 14569971.3213 
control 33051092.35538* 12823393 .013 7267933.6587 58834251.0521 
control bulbar -44264279.73077* 14709440 .004 -73839591.1003 -14688968.3612 
limb -33051092.35538* 12823393 .013 -58834251.0521 -7267933.6587 
CHOP bulbar limb -28225787.20333 19263255 .150 -67000708.8205 10549134.4138 
control -2088262.16667 22393079 .926 -47163192.9713 42986668.6380 
limb bulbar 28225787.20333 19263255 .150 -10549134.4138 67000708.8205 
	   111	  
control 26137525.03667 19263255 .181 -12637396.5805 64912446.6538 
control bulbar 2088262.16667 22393079 .926 -42986668.6380 47163192.9713 
limb -26137525.03667 19263255 .181 -64912446.6538 12637396.5805 
PDI bulbar limb 1700386.68615 7218506 .815 -12813392.1913 16214165.5637 
control -2434846.73077 8280194 .770 -19083292.8929 14213599.4313 
limb bulbar -1700386.68615 7218506 .815 -16214165.5637 12813392.1913 
control -4135233.41692 7218506 .569 -18649012.2944 10378545.4606 
control bulbar 2434846.73077 8280194 .770 -14213599.4313 19083292.8929 
limb 4135233.41692 7218506 .569 -10378545.4606 18649012.2944 
Serca2 bulbar limb 26747906.57333 30509167 .385 -34628620.2302 88124433.3769 
control -40497081.51282 34777457 .250 -110460299.8942 29466136.8685 
limb bulbar -26747906.57333 30509167 .385 -88124433.3769 34628620.2302 
control -67244988.08615* 29705730 .028 -127005208.6799 -7484767.4924 
control bulbar 40497081.51282 34777457 .250 -29466136.8685 110460299.8942 
limb 67244988.08615* 29705730 .028 7484767.4924 127005208.6799 
*. The mean difference is significant at the 0.05 level. 
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